<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098588</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1522356</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Hypothesis and Theory</subject></subj-group></subj-group></article-categories><title-group><article-title>New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Elkoshi</surname><given-names>Zeev</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2535211/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Research and Development Department, Taro Pharmaceutical Industries Ltd</institution>, <addr-line>Haifa</addr-line>, <country>Israel</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Eddie A. James, Benaroya Research Institute, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ulrike Steffen, University of Erlangen Nuremberg, Germany</p><p>Hui Ma, Trinity Biomedical Sciences Institute, Faculty of Engineering, Mathematics and Science, Trinity College Dublin, Ireland</p></fn><corresp id="fn001">*Correspondence: Zeev Elkoshi, <email xlink:href="mailto:zeev.elkoshi@gmail.com">zeev.elkoshi@gmail.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1522356</elocation-id><history><date date-type="received"><day>04</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>03</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Elkoshi</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Elkoshi</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The onset and relapse of autoimmune diseases (AIDs) are triggered by autoimmune attacks on target tissues. However, symptoms are unlikely to appear if damaged cells are rapidly replaced. Addressing the implications of this premise, the present work examines the balance between target tissue destruction and recovery rates as a key factor in the mechanisms of remissions and relapses in AIDs. The theory, supported by published clinical data, suggests that remissions are improbable in AIDs characterized by slow target tissue recovery. Conversely, a high recovery rate is a necessary (though not sufficient) condition for cycles of remission and relapse in AIDs. A high recovery rate of target tissue explains the tendency for remitting-relapsing disease, the likelihood of detecting autoantibodies in healthy individuals and the responsiveness to immunosuppressive drug treatments. Analyzing specific AIDs through the balance of tissue destruction and recovery yields several insights. For example, the difference between androgenic alopecia, a non-remitting-relapsing disease and alopecia areata, a remitting-relapsing AID, is elucidated. A new mechanism underlying relapses and remissions in alopecia areata based on hair follicle regeneration rate is proposed. It is suggested that mild Graves&#x02019; disease and remitting Hashimoto&#x02019;s thyroiditis would be responsive to corticosteroids or immunosuppressant treatment, unlike more severe forms of these diseases. Additionally, it is proposed that the transition from remitting-relapsing multiple sclerosis to secondary progressive multiple sclerosis is associated with the depletion of brain compensatory reserves. Notably, it is concluded that exercise will not play a neuroprotective role in secondary progressive multiple sclerosis.</p></abstract><kwd-group><kwd>autoimmune diseases</kwd><kwd>remission</kwd><kwd>relapse</kwd><kwd>tissue recovery rate</kwd><kwd>autoantibodies</kwd><kwd>immunosuppressants</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="2"/><ref-count count="129"/><page-count count="13"/><word-count count="7419"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Relapses refer to periods when a disease&#x02019;s severity intensifies, while remissions are periods when its severity diminishes. Many autoimmune diseases (AIDs) are characterized by alternating phases of relapse and remission, with symptoms flaring up and then subsiding. Conditions following this pattern include multiple sclerosis (MS), rheumatoid arthritis, inflammatory bowel disease, lupus, myasthenia gravis, and psoriasis (<xref rid="B1" ref-type="bibr">1</xref>). These cycles of remission and relapse are driven by fluctuating immune reaction that sways between pro- and anti-inflammatory responses. However, in certain AIDs other factors may be involved in remission (MS for example). The onset and relapse of AIDs may be triggered by internal factors, such as epitope spreading, reduced immune regulation, and an increased inflammatory response (<xref rid="B2" ref-type="bibr">2</xref>). External factors such as viral infections, low exposure to sunlight (<xref rid="B3" ref-type="bibr">3</xref>) and stress (<xref rid="B4" ref-type="bibr">4</xref>) can also trigger the onset and relapse of AIDs. Remission may occur when inflammation subsides, a viral infection resolves, or stress is alleviated. While immune system activity is often proposed to underlie the cycles of flare and abatement in AIDs (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>), the role of target tissue recovery rate is less commonly discussed as a factor in the onset, relapse, and remission of AIDs. An earlier publication on the refractoriness of certain AIDs to immunosuppressants suggests that the balance between target tissue destruction and recovery rates, either during an autoimmune attack or following immunosuppressive treatment, is crucial for determining tissue recovery and symptom improvement (<xref rid="B6" ref-type="bibr">6</xref>). The present article adopts a similar approach to explore remissions and relapses in AIDs and addresses the puzzle of harmless autoantibodies in healthy individuals.</p></sec><sec id="s2"><title>Remissions and relapses in autoimmune diseases: understanding their onset and termination</title><p>Define the net tissue generation rate during immune attack, <italic>R</italic>,&#x000a0;as:</p><disp-formula id="eq1">
<label>(1)</label>
<mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>R</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:math>
</disp-formula><p>where <italic>Rreg</italic> is the regeneration rate of the tissue under the autoimmune attack, and <italic>Rdes</italic> is the destruction rate of the tissue due to the autoimmune attack. When <italic>R</italic> &#x0003e; 0, the autoimmune response is unlikely to trigger symptoms, as the regeneration rate exceeds the destruction rate, thereby preserving tissue mass during the immune attack. Symptoms of AIDs appear when <italic>R</italic>
<bold>&#x0003c;</bold> 0 which occurs when <italic>Rreg</italic>
<bold>&#x0003c;</bold>
<italic>Rdes</italic>. Under this condition, continued immune attack will ultimately destroy all tissue cells. In such cases, spontaneous remission is unlikely, as any newly regenerated cells will be damaged by the ongoing immune response, preventing the tissue recovery necessary for symptom relief and remission. Clinical improvement (remission) is a consequence of tissue recovery which can take place, only when inflammation has sufficiently dampened, resulting in <italic>R</italic> &#x0003e; 0. This may happen spontaneously or following drug treatment. Without remission, a relapse is improbable, establishing a monophasic disease. Thus, a necessary condition for tissue remission (and a possible subsequent relapse) in AIDs is <italic>R</italic> &#x0003e; 0. Immunosuppressive drug treatments may lower the <italic>Rdes</italic> value, thereby inducing remission (<italic>R</italic> &#x0003e; 0).</p><p>If the tissue has an inherently negligible regeneration rate (<italic>Rreg</italic> = 0), <italic>R</italic> will be negative, even with a low destruction rate (<italic>Rdes</italic>). Consequently, tissues with negligible regeneration rates are unlikely to recover, making remission unlikely.</p><p>In certain tissues targeted by autoimmune attacks, variations in cell function also influence the likelihood of remission or relapse. For instance, fluctuations in insulin secretion rates by pancreatic &#x003b2; cells in Type 1 Diabetes (T1D) or changes in thyroid hormone secretion by thyroid follicles in Hashimoto&#x02019;s Thyroiditis (HT) can trigger symptom remission or relapse. The impact of these cells on remission or relapse depends not only on their quantity but also on the rate at which they produce and release hormones. In other AIDs, such as MS, functional impairment caused by immune reaction is a more appropriate measure for relapses and remissions. The term &#x0201c;tissue activity&#x0201d; will be used to describe target tissue function. It is convenient to define <italic>Ra</italic>, the net rate of tissue activity during an autoimmune attack, as:</p><disp-formula id="eq2">
<label>(2)</label>
<mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mo>)</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mo>)</mml:mo></mml:mrow></mml:math>
</disp-formula><p>where <italic>Ra+</italic> represents the increase in <italic>Ra</italic> by factors like tissue regeneration or activating agents, while <italic>Ra-</italic> indicates the decrease in <italic>Ra</italic> due to tissue destruction following autoantibody attack, or from impairment of cell function by deactivating hormones or toxic substances. Throughout this text <italic>Ra+</italic> will be referred to as &#x0201c;recovery rate&#x0201d;. Remission is expected when <italic>Ra</italic> &#x0003e; 0, while relapse is expected when <italic>Ra</italic>
<bold>&#x0003c;</bold> 0.</p><p>
<xref rid="eq2" ref-type="disp-formula">Equation 2</xref> can be viewed as a generalization of <xref rid="eq1" ref-type="disp-formula">Equation 1</xref>, as the net tissue generation rate is one of the factors that contribute to the overall rate of tissue activity. A prerequisite for applying <xref rid="eq2" ref-type="disp-formula">Equation 2</xref> is the presence of a minimum number of active cells in the target tissue; if the targeted tissue experiences significant damage, no activity is expected</p><p>Here are five examples of chronic diseases (four AIDs and one non-AID) that typically do not go into remission in most patients:</p><sec id="s2_1"><title>Type 1 diabetes (advanced)</title><p>T1D is the most common chronic AID in young patients. It is caused by the destruction of pancreatic endocrine &#x003b2;-cells, which are responsible for producing insulin in the islets of Langerhans. As a result, the body becomes deficient in insulin and experiences hyperglycemia. The primary treatment for T1D involves regular insulin injections to control hyperglycemia. A defining feature of T1D is the immune system&#x02019;s recognition of &#x003b2;-cell proteins as autoantigens, leading to an autoimmune response involving autoreactive CD4+ and CD8+ T cells, as well as autoantibodies (<xref rid="B7" ref-type="bibr">7</xref>). The regenerative capacity of the pancreatic endocrine islets including that of &#x003b2; cells is limited in adults (<xref rid="B8" ref-type="bibr">8</xref>). In newly diagnosed T1D patients, many experience a decrease in insulin requirements after starting insulin therapy. This phase is known as the &#x02018;honeymoon period.&#x02019; A study on new-onset T1D patients found that during the first 18 months of the disease, 12.3% of patients entered total remission (median duration of 6 months), and 18.3% experienced partial remission (median duration of 6 months). However, the percentage of patients in remission decreased after 6 months (<xref rid="B9" ref-type="bibr">9</xref>). This topic will be explored in greater detail later. Nevertheless, remissions in advanced T1D, after most &#x003b2;-cells have been destroyed, are extremely rare since almost all T1D patients require lifelong insulin replacement therapy (<xref rid="B10" ref-type="bibr">10</xref>). The author is not aware of any publications describing remission (i.e., no need for insulin replacement therapy) in advanced T1D after the honeymoon period has ended. The slow recovery rate in advanced T1D likely underlies this monophasic pattern.</p></sec><sec id="s2_2"><title>Androgenic alopecia</title><p>Pattern or androgenetic alopecia (AGA) is a hereditary condition caused by an increased sensitivity to androgens, affecting about 50% of both men and women. AGA is not an AID. It is marked by the gradual thinning of terminal hair on the scalp, usually beginning after puberty and following a characteristic pattern unique to each gender. Activation of androgen receptors shortens the anagen (growth) phase of the hair cycle, leading to follicular miniaturization. As a result, hair follicles become progressively finer and shorter, sometimes failing to grow long enough to reach the skin&#x02019;s surface (<xref rid="B11" ref-type="bibr">11</xref>). Androgens act through the intracellular androgen receptor (AR). In hair follicles, ARs are mainly expressed by the dermal papilla (<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>). The prevailing hypothesis proposes that the androgen/AR complex modifies the production of regulatory factors within the dermal papilla, affecting both its own growth and the growth of the follicle&#x02019;s epithelial components through autocrine and paracrine signaling (<xref rid="B15" ref-type="bibr">15</xref>). For example, stimulation of TGF-&#x003b2; production in HF papilla cells from AGA patients inhibited normal epithelial cells growth <italic>in vitro</italic> (<xref rid="B16" ref-type="bibr">16</xref>). AGA is a chronic and progressive disease. AGA entails inflammatory characteristics, at least in part of the patients (<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>). Regeneration of damaged hair follicle epithelial cells is impaired in AGA patients. Androgens disrupt the balance between Wnt agonists and antagonists in dermal papilla cells, inhibiting the differentiation of hair follicle stem cells (<xref rid="B21" ref-type="bibr">21</xref>). In addition, a defective conversion of HF stem cells to progenitor cells was reported in AGA (<xref rid="B22" ref-type="bibr">22</xref>). Since AGA is a chronic disease that involves progressive destruction of a target tissue (hair follicle), Eq. 1 may be applied to assess the likelihood of remission, although AGA is not an autoimmune condition. The low rate of scalp HF regeneration in AGA implies that remissions are not expected (<italic>R</italic>
<bold>&#x0003c;</bold> 0). To the best of the author&#x02019;s knowledge, no spontaneous remissions of AGA are reported in the literature.</p></sec><sec id="s2_3"><title>Hashimoto&#x02019;s thyroiditis</title><p>The thyroid gland is characterized by its slow cell turnover rate, with cells estimated to divide approximately once every 10 years and around 5 times during adulthood (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). Although recent findings indicate an increase in thyroid volume following hemithyroidectomy (used to treat goiter) due to epithelial hyperplasia, this compensatory mechanism has minimal or no impact on symptomatology (<xref rid="B25" ref-type="bibr">25</xref>). The destruction of thyrocytes by autoreactive T cells and the low regeneration capacity of the thyroid gland leads, over time, to an extensive destruction of thyroid follicular cells in many patients with Hashimoto&#x02019;s thyroiditis (HT) (<xref rid="B26" ref-type="bibr">26</xref>). However, remissions are reported in some HT patients. Takasu et&#x000a0;al. (<xref rid="B27" ref-type="bibr">27</xref>) reported that among a group of 92 HT patients treated with levothyroxine, 22 patients (24%) experienced remission after the treatment was stopped. In this study, patients in remission were defined as those who remained euthyroid for periods ranging from 1 to 8 years after treatment cessation. In another study, 8.1 years follow-up of children with HT revealed that over the years, 16% of children presenting with overt hypothyroidism stopped therapy (<xref rid="B28" ref-type="bibr">28</xref>). The present study suggests that increased production of thyroid hormones by a cluster of active thyroid follicles surviving the immune attack may contribute to symptom improvement in HT patients experiencing remission.</p></sec><sec id="s2_4"><title>Graves&#x02019; disease</title><p>Graves&#x02019; disease (GD) is an autoimmune disorder that primarily&#x000a0;targets the thyroid gland and is the leading cause of hyperthyroidism. In GD, hyperthyroidism is caused by autoantibodies targeting the thyroid stimulating hormone receptor (TSHR), which act as agonists to stimulate excessive thyroid hormone production (<xref rid="B29" ref-type="bibr">29</xref>). Although spontaneous recovery from GD is rare, it has been reported in stress-induced GD cases following relief from stress (<xref rid="B4" ref-type="bibr">4</xref>). Remissions have also been observed in some GD patients after treatment with propranolol (<xref rid="B30" ref-type="bibr">30</xref>). Despite the very limited regenerative capacity of thyrocytes, existing thyroid cells can respond to external stimuli&#x02014;such as TSH, glucocorticoids, catecholamines, and pro-inflammatory cytokines&#x02014;by adjusting thyroid hormone secretion. At the same time, the active thyroid hormone T3 is degraded by iodothyronine deiodinases (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). The balance between T3 production (stimulated by TSH and by TSHR stimulating autoantibodies and suppressed by TSHR blocking autoantibodies) and T3 degradation, dictates whether hypothyroidism in GD progresses or resolves. Enzymatic degradation of T3, as with any enzymatic process, reaches a maximum steady-state value (a plateau) at high substrate concentrations, in line with the Michaelis-Menten equation (<xref rid="B33" ref-type="bibr">33</xref>). When substrate concentration exceeds the level required to reach this plateau, the negative feedback mechanism is lost, meaning an increase in T3 generation rate is no longer counteracted by a rise in its degradation rate (as the enzymatic degradation rate remains constant). This explains the onset of GD symptoms when <italic>Ra</italic> &#x0003e; 0. GD remission occurs when <italic>Ra</italic>
<bold>&#x0003c;</bold> 0. However, in cases of severe GD with very high T3 production, a moderate reduction in T3 generation rate (for example, following drug treatment or stress reduction in stress-induced GD) may not be sufficient to shift the balance and achieve remission. Therefore, severe GD does not respond to drugs, such as propranolol, that only moderately reduce T3 production, and &#x02018;spontaneous&#x02019; remissions of GD are expected only in mild cases. Indeed, the remissions reported by Willems et&#x000a0;al. (<xref rid="B4" ref-type="bibr">4</xref>) and Codaccioni et&#x000a0;al. (<xref rid="B30" ref-type="bibr">30</xref>) involved only patients with mild GD. Remissions in patients treated with propranolol were observed in a subgroup with significantly lower T3 levels compared to those without remissions (<xref rid="B30" ref-type="bibr">30</xref>). Similarly, none of the patients with stress-induced GD exhibited thyroid eye disease or a large goiter (<xref rid="B4" ref-type="bibr">4</xref>), the classical signs of severe GD. The author of this article postulates that, in contrast to severe GD (<xref rid="B6" ref-type="bibr">6</xref>), patients with mild GD may benefit from immunosuppressive treatment, including corticosteroids.</p></sec><sec id="s2_5"><title>Primary biliary cholangitis</title><p>Primary biliary cholangitis (PBC) is a long-term AID primarily seen in middle-aged women, characterized by cholestasis. The condition involves the gradual destruction of intrahepatic bile ducts and the presence of circulating anti-mitochondrial antibodies. In severe cases, PBC can progress to complications such as fibrosis, cirrhosis, end-stage liver disease, and even death. The impairment of the Cl&#x02212;/HCO3&#x02212; exchanger AE2 in cholangiocytes and lymphoid cells leads to biliary epithelial cell (BEC) destruction, and in severe cases, to the destruction of hepatocytes as well and an impairment of liver regenerative capacity (<xref rid="B6" ref-type="bibr">6</xref>). Indeed, spontaneous or treatment-related PBC remissions are very rare (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>In contrast to the five aforementioned examples, AIDs targeting tissues with a high recovery rate after damage, are generally more prone to remissions, which may or may not be followed by exacerbations. More specifically, a high recovery rate of the target tissue is a necessary (but not sufficient) condition for the remission of an autoimmune disease.</p><p>Here are five examples of autoimmune diseases prone to remissions and relapses:</p></sec><sec id="s2_6"><title>Type 1 diabetes (early disease)</title><p>T1D clinical onset with classic hyperglycemic symptoms occurs when less than 30% of &#x003b2;-cells remain. As mentioned above, shortly after T1D diagnosis, many patients enter a partial remission known as the &#x0201c;honeymoon phase,&#x0201d; lasting a few months. During this time, the remaining &#x003b2;-cells produce enough insulin to reduce the need for external insulin. However, this phase is temporary, and all patients eventually relapse, requiring lifelong insulin therapy (<xref rid="B35" ref-type="bibr">35</xref>). The availability of a considerable number of <italic>active</italic> &#x003b2;-cells shortly after T1D onset allows the remission period observed in many patients.</p></sec><sec id="s2_7"><title>Alopecia areata</title><p>Hair follicles (HFs) in the anagen phase of the hair cycle have a high regeneration rate (<xref rid="B36" ref-type="bibr">36</xref>). Alopecia areata (AA) is a form of non-scarring hair loss in humans, characterized by the collapse of hair follicle immune privilege and the infiltration of lymphocyte around the anagen bulb (<xref rid="B37" ref-type="bibr">37</xref>). HF stem cells are spared during AA (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). The author of this work believes that, in contrast to AGA, stem cell activity is also preserved during AA, which secures the high regeneration rate of HFs. Indeed, remissions and relapses in alopecia areata are common (<xref rid="B40" ref-type="bibr">40</xref>). Immune privilege (IP) of anagen hair follicles is a unique characteristic that protects follicles from immune attacks. HF-IP effectively suppresses the immune cell response by establishing an immunosuppressive signaling environment in anagen HFs. Both stress and viral infections can trigger HF-IP collapse (<xref rid="B41" ref-type="bibr">41</xref>), mediated by immune cell secretion of IFN-&#x003b3; (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Spontaneous restoration of HF-IP is promoted by the intrafollicular production of endogenous IP guardians and the release of immunoinhibitory neuropeptides (<xref rid="B37" ref-type="bibr">37</xref>). Breitkopf et&#x000a0;al. (<xref rid="B44" ref-type="bibr">44</xref>) reported the upregulation of somatostatin in the middle (sheath) and lower (bulb) portions of human HF. These authors have shown that PBMCs, cultured with stimulatory allogeneic epidermal cells and somatostatin, secreted significantly less IFN- &#x003b3; than controls, suggesting somatostatin as a secretory factor potentially contributing to the HF-IP repertoire. Ito et&#x000a0;al. (<xref rid="B45" ref-type="bibr">45</xref>) identified &#x003b1;-melanocyte stimulating hormone (&#x003b1;-MSH), insulin growth factor-1 (IGF-1), and tumor growth factor &#x003b2;1 (TGF-&#x003b2;1), all of which are locally generated in the skin, as factors that may potentially restore HF-IP following its collapse. These studies collectively suggest that the collapse and subsequent restoration of immune privilege drive the relapse-remission cycles in AA. The present study proposes an alternative mechanism, potentially operating alongside immune privilege modulation, in driving the cyclic pattern observed in AA. Qin et&#x000a0;al. (<xref rid="B46" ref-type="bibr">46</xref>) demonstrated that IFN-&#x003b3; inhibits the differentiation of adult liver and bone marrow hematopoietic stem cells in mice by blocking Notch signaling activation. The Notch signaling pathway is crucial for maintaining hair follicle growth and development (<xref rid="B47" ref-type="bibr">47</xref>). It is therefore plausible that IFN-&#x003b3; similarly inhibits hair follicle stem cell proliferation through Notch signaling suppression, potentially preventing remission in AA while allowing relapse. Conversely, IGF-1, identified as an HF-IP promoter, also enhances mesenchymal stem cell self-renewal and proliferation (<xref rid="B48" ref-type="bibr">48</xref>) and may similarly support hair follicle stem cell proliferation. This would facilitate hair follicle cell regeneration. According to the premises of this study, a faster follicular cell regeneration rate could prevent relapses while enabling remissions.</p><p>It can be concluded that a balance between IFN-&#x003b3; (secreted by activated T cells and NK cells) and the endogenous IP guardians, determines whether hair sheds or grows during AA. This balance can influence hair growth either through its effect on the follicular immune barrier or by affecting the rate of follicular cell regeneration.</p><p>In terms of <xref rid="eq2" ref-type="disp-formula">Equation 1</xref>, <italic>R</italic>, the net rate of hair growth, is determined by the difference between <italic>Rreg</italic> (the hair growth rate) and <italic>Rdes</italic> (the hair destruction rate). Hair growth is promoted by agents that support HF-IP such as somatotropin, &#x003b1;-MSH, IGF-1, and TGF-&#x003b2;1 or by those that stimulate HF cells regeneration rate, like &#x003b1;-MSH. Hair destruction is driven by agents that either disrupt anagen HF-IP or slow down HF cell regeneration rates, such as IFN-&#x003b3; in both cases. When <italic>R</italic> &#x0003e; 0, the anagen phase continues and hair grows. When <italic>R</italic>
<bold>&#x0003c;</bold> 0, HFs experience dystrophy, transitioning into the catagen and telogen phases, which halts hair growth and leads to hair shaft breakage and shedding. Remission in AA may occur with occasional increases in local concentrations of IP-preserving agents or those that enhance regeneration rates. Relapse may occur with a decrease in these agents or an increase in IFN-&#x003b3; concentration (due to stress or viral infection). Notably, without a consistently high regeneration rate of anagen HFs in AA, remissions and subsequent relapses would be unlikely.</p></sec><sec id="s2_8"><title>Autoimmune pancreatitis</title><p>As has been asserted, the regenerative capacity of the pancreas endocrine islets in adults is limited. In contrast, the exocrine pancreas can regenerate and fully recover from conditions like acute pancreatitis (<xref rid="B8" ref-type="bibr">8</xref>). Autoimmune pancreatitis (AIP) is an inflammatory disease that primarily affect the exocrine pancreas (<xref rid="B49" ref-type="bibr">49</xref>). Indeed, 80% spontaneous remission rate was reported in a group of 95 patients with untreated Type 1 autoimmune pancreatitis (pancreatic manifestation of IgG4-related disease) (<xref rid="B50" ref-type="bibr">50</xref>). Moreover, negative IgG4 staining of the duodenal papilla was the only independent predictor of spontaneous remission in AIP, whereas seropositivity was significantly associated with relapse (<xref rid="B51" ref-type="bibr">51</xref>). Since IgG4 is an antibody specifically associated with Type 1 AIP, these findings suggest that remission occurs when this specific immune response subsides, and relapse occurs when it reemerges. In other words, in Type 1 AIP, remissions and relapses are determined by changes in <italic>Rdes</italic> (Eq. 1), while <italic>Rreg</italic> remains relatively constant. It seems that AIP remission is induced by a reduction in immune response, and it is not surprising that corticosteroids are effective in ameliorating AIP (<xref rid="B50" ref-type="bibr">50</xref>). But this beneficial effect would not be observed if the regeneration rate of the exocrine pancreas was low.</p></sec><sec id="s2_9"><title>Inflammatory bowel diseases</title><p>The intestinal epithelium is typically renewed every 4<bold>&#x02013;</bold>5 days, making it one of the fastest-regenerating tissues in the human body (<xref rid="B52" ref-type="bibr">52</xref>). As a result, inflammatory bowel diseases (IBD) are expected to follow a pattern of relapse and remission. Indeed, IBD progress with alternating phases of remission and flare-ups (<xref rid="B53" ref-type="bibr">53</xref>). Given the high turnover rate of the intestinal epithelium, these cycles are largely influenced by the degree of bowel inflammation. In fact, an increase in inflammatory markers such as fecal calprotectin can predict relapses, with a pooled sensitivity of 0.720 and specificity of 0.740 (<xref rid="B53" ref-type="bibr">53</xref>). If epithelial turnover were low (low <italic>Rreg</italic> value), a detection method with a lower limit of detection would be required to predict relapses, as even minimal levels of inflammatory markers could result in <italic>R</italic>
<bold>&#x0003c;</bold> 0. The high renewal capacity of the intestines allows a large proportion of IBD patients to have mucosal inflammation without clinical symptoms (<xref rid="B54" ref-type="bibr">54</xref>).</p></sec><sec id="s2_10"><title>Multiple sclerosis</title><p>Multiple sclerosis is an inflammatory disease of the central nervous system (CNS) characterized by both inflammatory and degenerative processes that impact both white and grey matter. The key neuropathological features of MS include demyelination, inflammation, astrocytic gliosis, and neurodegeneration, with neurodegeneration now recognized as the primary pathological driver of clinical progression (<xref rid="B55" ref-type="bibr">55</xref>). Multiple sclerosis is considered an AID. Although there is no consensus, myelin-related antigens are suspected to play a role, with some studies also suggesting that antigens on the surfaces of neuronal or glial cells may be involved (<xref rid="B3" ref-type="bibr">3</xref>). Eighty percent of MS patients exhibit a pattern known as relapsing-remitting MS (RRMS), characterized by cycles of exacerbation followed by substantial remission. Relapses typically occur every few years, with symptoms&#x02014;such as visual, motor, sensory, or autonomic disturbances affecting bowel and bladder function&#x02014;depending on the location of the inflammatory attack in the CNS. These relapses can last days or weeks and are followed by remission, though some residual disability often remains. Over time, about one-third of patients with relapsing-remitting MS experience increasing disability, while the frequency of relapses and remissions diminishes, contrary to reasoning. At the point where relapse and remission wane, the condition is termed secondary-progressive MS (SPMS) (<xref rid="B56" ref-type="bibr">56</xref>). Applying Eq. 2 to RRMS, <italic>Ra</italic> is the patient&#x02019;s motor function, <italic>Ra-</italic> is comprised of all factors that impair motor function while <italic>Ra+</italic> encompasses all factors that improve it. In this respect, <italic>Ra-</italic> includes rates of nerve demyelination and axonal injury due to immune attack. <italic>Ra+</italic> includes nerve remyelination rate, restoration rate of axonal function and brain&#x02019;s compensatory effects reflected by an increased cortical response to nerve injury (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>). A relapse is observed when <italic>Ra</italic>
<bold>&#x0003c;</bold> 0 (<italic>Ra+</italic>
<bold>
<italic>&#x0003c;</italic>
</bold>
<italic>Ra-</italic>). A remission is observed when <italic>Ra</italic> &#x0003e; 0 (<italic>Ra+</italic> &#x0003e; <italic>Ra-</italic>). Immune-modulating drugs significantly reduce relapse frequency in relapsing-remitting multiple sclerosis by suppressing the immune attack, thereby lowering the <italic>Ra-</italic> value. Risk factors for MS include Epstein&#x02013;Barr virus (EBV) seropositivity, low vitamin D levels, and obesity during adolescence (<xref rid="B3" ref-type="bibr">3</xref>). Each of these variables induces a pro-inflammatory reaction (<xref rid="B59" ref-type="bibr">59</xref>&#x02013;<xref rid="B61" ref-type="bibr">61</xref>) that may trigger the onset of MS. In addition, the role of epitope spreading in the onset and relapse of multiple sclerosis is well-documented in experimental models and has also been observed in a prospective study of pediatric-onset CNS demyelinating diseases, specifically in patients who later developed MS (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Low sun exposure, leading to decreased vitamin D levels, and mononucleosis, may trigger MS relapses. Additionally, stress has been shown to induce relapses in MS patients (<xref rid="B64" ref-type="bibr">64</xref>). Brief periods of stress, lasting from minutes to hours, boost pro-inflammatory innate and adaptive immune responses (<xref rid="B65" ref-type="bibr">65</xref>). Referring back to Eq. 2, relapses (<italic>Ra</italic>
<bold>&#x0003c;</bold> 0) may occur when brain local inflammation increases due to epitope spreading, temporary stress, temporary vitamin D depletion or EBV virion spread during the lytic phase of EBV life cycle, leading to demyelination and axonal injury. These effects are counteracted by remyelination and brain compensatory effects which may lead to remission (<italic>Ra</italic> &#x0003e; 0). Self-damping of inflammation may precede remyelination (<xref rid="B66" ref-type="bibr">66</xref>). Brain compensatory mechanisms result in improved motor function and physical ability typically observed during remission. This enhanced physical ability encourages increased physical activity, which is known to induce an anti-inflammatory effect (<xref rid="B67" ref-type="bibr">67</xref>). Accordingly, autoantibodies are detected in 86% of MS patients during the relapse phase, whereas only 30% of these patients test positive during remission (<xref rid="B68" ref-type="bibr">68</xref>). It is hypothesized that brain compensatory reserves diminish as MS progresses (<xref rid="B57" ref-type="bibr">57</xref>). A study involving MS patients supports this hypothesis (<xref rid="B69" ref-type="bibr">69</xref>). Assuming that brain reserves decline over time, the frequency of remissions must also decrease correspondingly. This, in turn, leads to a reduction in the frequency of relapses. When brain compensatory reserves reach a critical low level, tipping the balance in Eq. 2 towards a negative <italic>Ra</italic> value, RRMS converts into SPMS. Taken together, relapses in MS are a result of internal as well as environmental and recreational factors that induce immune reaction. The capacity of the CNS to regenerate or compensate for the loss of function is necessary for the induction of remission. When this capacity is lost, a period of continuous deterioration is established.</p><p>Reducing exposure to environmental factors that trigger MS could lower relapse frequency. This may be achieved through methods such as increasing sunlight exposure (<xref rid="B3" ref-type="bibr">3</xref>), vaccinating against EBV (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>), or managing stress (<xref rid="B72" ref-type="bibr">72</xref>). On the other hand, exercise, which is known to positively influence neural imaging outcomes and boost peripheral brain-derived neurotrophic factor (<xref rid="B73" ref-type="bibr">73</xref>), is believed to play a neuroprotective role or even a neuro-regenerative role in RRMS (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>). The author of this article suggests that, while exercise may improve fitness and quality of life throughout disease progression, any potential neuroprotective effect of exercise in MS is likely limited to the RRMS period, before brain functional reserves are exhausted and the compensatory response is lost.</p></sec></sec><sec id="s3"><title>Unraveling the mystery of benign autoantibodies in healthy individuals</title><p>Many autoantibodies reported in cancer and AIDs are also observed in healthy individuals (<xref rid="B76" ref-type="bibr">76</xref>&#x02013;<xref rid="B80" ref-type="bibr">80</xref>), evidently with no induction of AIDs. These autoantibodies will be referred to as common autoantibodies. One subset of these common autoantibodies is termed natural antibodies. Unlike adaptive antibodies, natural antibodies are produced by B1 lymphocytes (characterized by CD20+CD27+CD43+CD70&#x02212; markers) and marginal-zone B cells (<xref rid="B81" ref-type="bibr">81</xref>). These natural antibodies do not undergo affinity maturation through antigen exposure or undergo extensive somatic hypermutation, and therefore exhibit low reactivity against self-antigens. Another group of common autoantibodies may originate from cross-reactive antibodies developed against infectious agent proteins, where the resemblance between foreign and self-peptides can stimulate the activation of self-reactive T or B cells (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B82" ref-type="bibr">82</xref>). Natural low affinity autoantibodies are mainly IgM, whereas the highly reactive group includes mainly IgG autoantibodies (<xref rid="B83" ref-type="bibr">83</xref>). While&#x000a0;the reduced reactivity of natural autoantibodies may account for their low pathogenicity in triggering AIDs, it remains unclear why cross-reactive antibodies generated from exposure to external pathogens do not induce an autoimmune attack in otherwise healthy individuals. This article suggests that this benign reactivity may be due to a high recovery rate of the target tissue, which prevents symptom manifestation. In contrast, in AIDs with a low tissue recovery rate, symptoms can develop even at relatively low autoantibody levels, as damaged cells are not quickly replaced. Autoantibody levels associated with diseases with low recovery rate are expected to be low in healthy individuals (possibly below analytical detection limits), as higher levels would likely trigger symptoms. There are four AIDs that target tissues with low recovery rate after injury: advanced adult T1D, Hashimoto thyroiditis (HT), Graves&#x02019; disease (GD), and advanced primary biliary cholangitis (PBC). Contrary to all other AIDs, these diseases do not respond to corticosteroid or immunosuppressant treatments, as elucidated in an earlier publication (<xref rid="B6" ref-type="bibr">6</xref>). Although the liver has a high capacity of regeneration after injury, it is speculated that this property is lost due to extensive damage to hepatocytes following advanced PBC (<xref rid="B6" ref-type="bibr">6</xref>). As demonstrated in the former sections, these AIDs are not associated by cycles of remission and relapse. The following discussion will demonstrate that common autoantibodies targeting antigens associated with non-relapsing-remitting AIDs&#x02014;such as T1D, GD, and PBC&#x02014;are rare in the general population (though not every rare autoantibody in the general population is linked to non-relapsing-remitting AIDs). Additionally, it will be shown that common autoantibodies with high prevalence in the general population are associated with relapsing-remitting AIDs (though not all autoantibodies associated with relapsing-remitting AIDs are highly prevalent in the general population). Autoantibodies associated with Hashimoto&#x02019;s thyroiditis exhibit low reactivity and therefore do not induce autoimmunity in either healthy individuals or HT patients; a high prevalent of these autoantibodies is not likely to trigger HT.</p><sec id="s3_1"><title>Autoimmune diseases linked to autoantibodies rare in the general population</title><sec id="s3_1_1"><title>Type 1 diabetes</title><p>Autoantibodies associated with T1D have been described against five autoantigens: insulin, GAD65, insulinoma-associated antigen-2 (IA-2), zinc transporter 8 (ZnT8) and tetraspanin 7. Accumulating evidence suggests that GAD autoantibodies (GADA) are not pathogenic in T1D and may even play a protective role (<xref rid="B84" ref-type="bibr">84</xref>). As for the other T1D-related autoantigens:</p><list list-type="order"><list-item><p>Insulin - Using commercial kits, anti-insulin autoantibodies were detected in about 60% of 36 T1D patients but were not detected among any of 56 controls (healthy individuals and T2D patients) (<xref rid="B85" ref-type="bibr">85</xref>).</p></list-item><list-item><p>ZnT8: In a study arm that included a cohort of 70 adult healthy individuals, only one subject exceeded the positivity cut-off limit for ZnT8 (<xref rid="B86" ref-type="bibr">86</xref>). In another study, the prevalence of anti-ZnT8 autoantibodies in healthy adult Chinese subjects was 1% (4 out of 405) compared to 24% in T1D patients (130/539) (<xref rid="B87" ref-type="bibr">87</xref>). Among 128 patients with T2D, none was positive for ZnT8A (<xref rid="B88" ref-type="bibr">88</xref>).</p></list-item><list-item><p>IA-2: Among 128 adult Bulgarian patients with T2D, one (0.78%) tested positive for IA-2A (<xref rid="B88" ref-type="bibr">88</xref>). In another study, 9 out of 67 adult T1D patients were found to be positive for IA-2, while none of the 10 healthy controls tested positive for antibodies against this antigen (<xref rid="B89" ref-type="bibr">89</xref>). In a third study involving 761 healthy individuals under the age of 40 (used as controls), none tested positive for anti-IA-2 autoantibodies (<xref rid="B90" ref-type="bibr">90</xref>).</p></list-item><list-item><p>Tetraspanin 7: Autoantibodies against tetraspanin 7 were detected in 1 out of 94 non-diabetic subjects (<xref rid="B91" ref-type="bibr">91</xref>). Similarly, only 1 out of 52 non-diabetic subjects tested positive for tetraspanin 7 antibodies, although low levels (below the cutoff) were observed in other subjects (<xref rid="B92" ref-type="bibr">92</xref>).</p></list-item></list><p>Among a group of 101 children and adolescents without T1D (1<bold>&#x02013;</bold>19 years old), only one (1%) was tested positive to anti-ZnT8 autoantibodies, one (1%) was tested positive to anti-insulin autoantibodies, and none was tested positive to anti-IA2 autoantibodies (<xref rid="B93" ref-type="bibr">93</xref>).</p><p>In summary, across all these studies, nearly all non-T1D individuals tested negative for autoantibodies against each of the four key T1D-related antigens.</p></sec><sec id="s3_1_2"><title>Hashimoto&#x02019;s thyroiditis</title><p>Patients with Hashimoto&#x02019;s thyroiditis produce antibodies against various thyroid antigens, most commonly anti-thyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg), with TSHR antibodies being less frequently detected (<xref rid="B94" ref-type="bibr">94</xref>). However, anti-Tg and anti-TPO antibodies do not directly cause thyroid cell destruction (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>). For this reason, autoantibodies against thyroid antigens do not trigger autoimmune reactions in either healthy individuals or HT patients. In HT, thyroid cell destruction is carried out by autoreactive T cells (<xref rid="B26" ref-type="bibr">26</xref>). Therefore, anti-TPO and anti-Tg antibodies may be observed in healthy individuals without triggering HT. Indeed, the prevalence of thyroid autoantibodies in the general population reported by Williams Textbook of Endocrinology (<xref rid="B97" ref-type="bibr">97</xref>) is 5% - 20% for anti-Tg and 8% - 27% for anti-TPO. A study in young asymptomatic females found a 5% prevalence for subjects positive only for anti-Tg antibodies, a 34% prevalence for those positive only for anti-TPO antibodies, and a 52% prevalence for subjects positive for both (<xref rid="B98" ref-type="bibr">98</xref>).</p></sec><sec id="s3_1_3"><title>Graves&#x02019; disease</title><p>In Graves&#x02019; disease, the primary autoantibodies target the thyroid stimulating hormone receptor (TSHR) on thyroid cells. These autoantibodies stimulate the thyroid gland to produce excessive thyroid hormones, resulting in hyperthyroidism (<xref rid="B29" ref-type="bibr">29</xref>). In a study of 302 healthy subjects, none tested positive for TSHR stimulating or TSHR blocking antibodies (<xref rid="B99" ref-type="bibr">99</xref>).</p></sec><sec id="s3_1_4"><title>Primary biliary cholangitis</title><p>Anti-mitochondrial antibodies (AMA), which target the E2 subunits of the 2-oxo acid dehydrogenase complexes (PDC-E2), serve as hallmark biomarkers for PBC found in 90-95% of affected patients. However, AMA is identified in less than 1% of healthy individuals (<xref rid="B100" ref-type="bibr">100</xref>).</p><p>Collectively, active autoantibodies that target tissues with limited recovery potential are linked to non-remitting-relapsing AIDs and are rarely detected in healthy individuals. Hashimoto&#x02019;s thyroiditis is an exception, as its autoantibodies are largely inert, with autoreactivity primarily mediated by T cells.</p></sec></sec><sec id="s4_1"><title>Autoimmune diseases linked to autoantibodies prevalent in the general population</title><p>In contrast to the rarity of common autoantibodies against antigens associated with non-remitting-relapsing AIDs in the general population, highly prevalent common autoantibodies in the general population are linked to remitting-relapsing AIDs (i.e., those involving tissues with high recovery capacity).</p><p>Some examples are provided below:</p><p>Shome et&#x000a0;al. (<xref rid="B76" ref-type="bibr">76</xref>) identified 77 autoantibodies reported in cancer or AIDs that are also present in healthy individuals. This was achieved through protein microarray analysis, using data from healthy individuals screened against a set of human proteins. Antibodies against STMN4, ODF2, RBPJ, AMY2A, EPCAM, and ZNF688 showed the highest prevalence. Of these six antigens, three are associated with AIDs. STMN4 antibodies (47% prevalence in healthy individuals) are linked to primary Sj&#x000f6;gren&#x02019;s syndrome (<xref rid="B101" ref-type="bibr">101</xref>). Polymorphisms in RBPJ antibodies (37% prevalence in healthy individuals) are associated with rheumatoid arthritis (<xref rid="B102" ref-type="bibr">102</xref>), ZNF688 autoantibodies (29% prevalence in healthy individuals) are linked to systemic lupus erythematosus (<xref rid="B103" ref-type="bibr">103</xref>). AMY2A is associated with autoimmune pancreatitis; however, the high prevalence of AMY2 reported by Shome et&#x000a0;al. contrasts with other published data (<xref rid="B104" ref-type="bibr">104</xref>) and shall not be discussed for this reason. Notably, primary Sj&#x000f6;gren&#x02019;s syndrome, rheumatoid arthritis, and systemic lupus erythematosus exhibit cycles of remission and relapse.</p><p>Antinuclear antibodies (ANA) are common in healthy individuals. Studies have shown that the prevalence of ANA associated with conditions like Sj&#x000f6;gren&#x02019;s syndrome, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and soft tissue rheumatism exceeds 31.7% (<xref rid="B78" ref-type="bibr">78</xref>). All of these AIDs undergo cycles of remission and relapse.</p><p>With specific reference to remission-prone AIDs discussed in the previous section:</p><sec id="s4_1_1"><title>Alopecia areata</title><p>Autoantibodies targeting one or more hair follicle antigens, which were found in the sera of all 39 alopecia areata patients, were also detected in 12 out of 27 (44%) healthy controls (<xref rid="B105" ref-type="bibr">105</xref>). As&#x000a0;discussed above, alopecia areata is a remitting-relapsing autoimmune disease.</p></sec><sec id="s4_1_2"><title>Multiple sclerosis</title><p>Antibodies against native glycosylated myelin oligodendrocyte glycoprotein (MOG) were measured by ELISA in patients with MS and controls. Although median values in healthy controls were lower than those in MS patients, the differences were modest and varied depending on the specific antibody type (IgM or IgG) and the phase of MS (<xref rid="B106" ref-type="bibr">106</xref>). In another study, anti-MOG antibodies were detected in 65 out of 252 healthy individuals (26%) (<xref rid="B107" ref-type="bibr">107</xref>). In a study comparing autoantibodies to myelin basic protein (MBP) in healthy individuals and patients with MS, the sera from both study groups contained approximately equal amounts of MBP-reactive IgM (<xref rid="B108" ref-type="bibr">108</xref>). It appears that major antibodies against MS antigens&#x02014;a disease with a remitting-relapsing phase in most patients&#x02014;are highly prevalent in healthy populations.</p></sec><sec id="s4_1_3"><title>Autoimmune pancreatitis</title><p>In one study, anti-smooth muscle antibodies (SMA) and anti-nuclear antibodies (ANA) were detected in 28% and 50% of AIP patients, respectively (<xref rid="B109" ref-type="bibr">109</xref>), while another study reported these antibodies in 17% and 76% of AIP patients, respectively (<xref rid="B110" ref-type="bibr">110</xref>). In healthy adults, high frequencies of ANA and SMA were observed, at 25% and 43%, respectively (<xref rid="B111" ref-type="bibr">111</xref>).</p><p>In conclusion, autoantibodies that target tissues with low regenerative capacity are associated with monophasic AIDs (i.e., AIDs that do not alternate between remissions and relapses) and are uncommon in the healthy population. In contrast, autoantibodies that target tissues with high regenerative potential are generally linked to relapsing-remitting AIDs and are highly prevalent in healthy individuals.</p></sec></sec></sec><sec sec-type="discussion" id="s5"><title>Discussion</title><p>Phylogenetically ancient vertebrates, including amphibians and fish, possess the ability to regenerate significant portions of their bodies. In contrast, mammals exhibit only a limited capacity for regeneration (<xref rid="B112" ref-type="bibr">112</xref>). The human body consists of tissues with widely varying regeneration rates. While tissues such as the heart and central nervous system (CNS) exhibit little to no self-renewal, the liver and pancreas have a slow turnover, whereas the skin, blood, and intestine undergo active renewal (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>). The primary factor behind these differences in regenerative capacity is the varying abundance of stem cells across these tissues. Additionally, dedifferentiation&#x02014;the process in which differentiated cells re-enter the cell cycle to generate new cells&#x02014;may also contribute to tissue regeneration in mammals. For instance, the dedifferentiation of renal proximal tubular epithelial cells plays a role in kidney regeneration following acute kidney injury. Transdifferentiation is another mechanism of cell regeneration, which in mammalian tissues must be triggered by external stimuli (<xref rid="B112" ref-type="bibr">112</xref>). For example, cholangiocytes can transdifferentiate into hepatocytes following liver injury (<xref rid="B115" ref-type="bibr">115</xref>). These cell renewal mechanisms contribute to the differences among human tissues in their ability to replace lost cells.</p><p>As suggested above, a high recovery rate is a necessary condition for remission of chronic diseases including AIDs. Diseases that target tissues with low recovery rate like adult advanced T1D, GD, AGA and SPMS rarely improve spontaneously. Similarly, when the recovery capacity is impaired by the immune system, for example in PBC, remissions are very rare. On the other hand, AIDs that target organs with high recovery potential that is not impaired by the disease, like AA, AIP or RRMS, tend to develop cycles of remissions and relapses. It is suggested that brain compensatory effect is important in triggering RRMS remissions, and the wane of compensatory reserve drives the transition from RRMS to SPMS.</p><p>The collapse of immune privilege in anagen hair follicles is considered a primary cause of AA onset and relapse, while the restoration of immune privilege has been proposed to induce AA remission. IFN-&#x003b3; has been shown to trigger immune privilege collapse, whereas molecules such as somatotropin, &#x003b1;-MSH, IGF-1, and TGF-&#x003b2;1 have been demonstrated to restore hair follicle immune privilege. This study proposes that IFN-&#x003b3;, known to block Notch signaling and inhibit the differentiation of liver and bone marrow hematopoietic stem cells in adult mice, may also inhibit the differentiation of hair follicle stem cells. Similarly, IGF-1, known to enhance mesenchymal stem cell self-renewal and proliferation, possibly drives the proliferation of hair follicle stem cells. This suggests a new mechanism underlying relapses and remissions in AA in addition to HF-IP control.</p><p>Using Lewis rat model of experimental autoimmune uveitis (EAU), the group of Gerhild Wildner have shown that EAU can be either monophasic or remitting, depending on the autoantigen used for induction. Uveitis could be induced by immunization with retinal soluble antigen (S-Ag), interphotoreceptor retinoid-binding protein (IRBP) or their peptide derivatives (PDSAg from S-Ag and R14 from IRBP) in Complete Freund&#x02019;s Adjuvant (CFA) as well as by the transfer of activated, antigen-specific T cells. EAU induced with PDSAg resulted in monophasic disease while immunization with peptide R14 led to remitting-relapsing disease. Similar effects were observed after the adoptive transfer of T cell lines specific for these peptides (<xref rid="B116" ref-type="bibr">116</xref>). The difference in the disease appearance (monophasic vs. remitting-relapsing) was attributed to &#x0201c;subtle differences in the T cell effector phenotype elicited&#x0201d; (<xref rid="B5" ref-type="bibr">5</xref>). The present work suggests a different explanation. The corneal epithelium is a self-renewing tissue sustained by stem cells located in the eye peripheral limbus. These limbal stem cells generate transient amplifying daughter cells, which renew the epithelium by migrating toward the center in a centripetal pattern (<xref rid="B117" ref-type="bibr">117</xref>). S-Ag (&#x003b2; arrestin-1) belongs to the family of arrestins which play a role in regulating stem cell characteristics, including self-renewal, in non-malignant stem cells (<xref rid="B118" ref-type="bibr">118</xref>). This may be also true with respect to IRBP since rat mesenchymal stem cells ameliorate EAU induced in rats by IRBP peptides (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>). If both S-Ag and IRBP antigens maintain ocular stem cell function, their attack by autoantibodies may impair ocular epithelium regeneration. Monophasic EAU following an attack by anti-SAg antibodies may be a result of a complete loss of ocular epithelial regenerative capacity, on the other hand, a remitting-relapsing disease following an autoimmune attack by anti-IRBP antibodies may be a consequence of a partial loss of this capacity.</p><p>The remission period in early T1D is widely discussed in the literature. The first hypothesis to explain this &#x02018;honeymoon period&#x02019; was the concept of &#x02018;&#x003b2;-cell rest.&#x02019; It proposed that exogenous insulin administration following T1D onset reduces the demand on &#x003b2;-cells, thereby improving insulin secretion and enhancing &#x003b2;-cell viability (<xref rid="B121" ref-type="bibr">121</xref>). Later it has been suggested that T1D is a cyclic relapsing&#x02013;remitting disease, driven by the immune system. It has been proposed that factors contributing to the cyclic nature of T1D include epitope spreading, &#x003b2;-cell proliferation, and regulatory T cell activity (<xref rid="B2" ref-type="bibr">2</xref>). Epitope spreading refers to the spontaneous expansion of the autoimmune response to new epitopes (subdominant or cryptic epitopes) in an epitope-specific manner (<xref rid="B122" ref-type="bibr">122</xref>). A few points should be noted regarding this model: (1) The assumption of epitope spreading is strongly supported by data from T1D patients (<xref rid="B123" ref-type="bibr">123</xref>) and various other autoimmune conditions, such as experimental autoimmune encephalomyelitis (<xref rid="B124" ref-type="bibr">124</xref>), experimental autoimmune uveoretinitis (<xref rid="B125" ref-type="bibr">125</xref>), membranous lupus nephritis with anti-GBM antibodies (<xref rid="B126" ref-type="bibr">126</xref>), and autoimmune bullous diseases (<xref rid="B127" ref-type="bibr">127</xref>). (2) Although increased &#x003b2;-cell proliferation has been observed in NOD mice just before the onset of overt diabetes (<xref rid="B128" ref-type="bibr">128</xref>), to the best of the author&#x02019;s knowledge, this has not been reported in humans, contrary to von Herrath et&#x000a0;al. premise (<xref rid="B2" ref-type="bibr">2</xref>). However, restored insulin secretion, rather than increased &#x003b2;-cell proliferation, may be responsible for the remission observed in many T1D patients after disease onset. Supporting evidence for this assumption includes the finding that glucose-induced insulin secretion was restored in pancreatic tissues isolated from living subjects shortly after a T1D diagnosis, following several days in a non-diabetogenic environment (<xref rid="B129" ref-type="bibr">129</xref>).</p><p>
<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref> summarizes the findings of this report.</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Autoimmune target tissue recovery rate, the tendency for a relapsing-remitting pattern, the likelihood of detecting autoantibodies in healthy individuals, and the response to immunosuppressive treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Disease</th><th valign="top" align="center" rowspan="1" colspan="1">Recovery rate</th><th valign="top" align="center" rowspan="1" colspan="1">Remission(s)</th><th valign="top" align="center" rowspan="1" colspan="1">Prevalence of autoantibodies in healthy individuals</th><th valign="top" align="center" rowspan="1" colspan="1">Immunosuppressant treatment efficacy (<xref rid="B6" ref-type="bibr">6</xref>)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">T1D (advanced)</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">no</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">low</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AGA</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">no</td><td valign="top" align="center" rowspan="1" colspan="1">not applicable (not an autoimmune disease)</td><td valign="top" align="center" rowspan="1" colspan="1">low</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GD (severe)</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">no</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">low</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PBC</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">no</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">low</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MS (SPMS)</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">no</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">low</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HT</td><td valign="top" align="center" rowspan="1" colspan="1">low in most patients/high in some patients (hypothesized)</td><td valign="top" align="center" rowspan="1" colspan="1">no (most patients)/yes (some patients)</td><td valign="top" align="center" rowspan="1" colspan="1">high (since autoantibodies are not reactive)</td><td valign="top" align="center" rowspan="1" colspan="1">low/not available (high effectivity is hypothesized in patients with high recovery rate)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T1D (early)</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">yes</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">effective but transient</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AA</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">yes</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">high</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AIP</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">yes</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">high</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MS (RRMS)</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">yes</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">high</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GD (mild)</td><td valign="top" align="center" rowspan="1" colspan="1">high</td><td valign="top" align="center" rowspan="1" colspan="1">yes</td><td valign="top" align="center" rowspan="1" colspan="1">low</td><td valign="top" align="center" rowspan="1" colspan="1">Not available but high effectivity is hypothesized</td></tr></tbody></table><table-wrap-foot><fn><p>T1D, Type 1 diabetes; AGA, Androgenic alopecia; GD, Graves&#x02019; disease; PBC, Primary biliary cholangitis; MS, Multiple sclerosis; HT, Hashimoto&#x02019;s thyroiditis; AA, Alopecia areata; AIP, Autoimmune pancreatitis.</p></fn></table-wrap-foot></table-wrap><p>
<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref> shows a correlation between target tissue recovery rate, the tendency for a relapsing-remitting pattern, the likelihood of detecting autoantibodies in healthy individuals, and the response to immunosuppressive treatment. AIDs targeting tissues with high recovery rates (due to high regenerative or compensatory capacities) tend to exhibit a relapsing-remitting pattern and respond to immunosuppressive treatments, including corticosteroids. Common autoantibodies highly prevalent in healthy individuals are often directed against target tissues with high recovery rates. In contrast, AIDs targeting tissues with low recovery rates do not display a relapsing-remitting pattern, do not respond to immunosuppressive treatments, and autoantibodies against their typical antigens are rarely found in healthy individuals.</p><p>
<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref> illustrates the distinction between AIDs targeting tissues with a high recovery rate and those targeting tissues with low recovery rate.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Comparative distinction between autoimmune diseases targeting tissues with high recovery rates and those targeting tissues with low recovery rates.</p></caption><graphic xlink:href="fimmu-16-1522356-g001" position="float"/></fig></sec><sec id="s6"><title>Summary</title><p>This report examines the role of target tissue recovery in autoimmune diseases, demonstrating that the rate of tissue recovery&#x000a0;affects the likelihood of a relapsing-remitting pattern, the presence of autoantibodies in healthy individuals, and the response to immunosuppressive treatment. The enigma of harmless autoantibodies in healthy populations is unraveled. Analyzing the role of tissue recovery across various autoimmune diseases yields clinically significant insights. The use of immunosuppressive drugs in mild Graves&#x02019; disease and remitting Hashimoto&#x02019;s thyroiditis is proposed. The decline in brain reserves is suggested as a key factor in the transition of multiple sclerosis from relapsing-remitting to secondary progressive disease. This decline limits the neuroprotective effect of exercise to the relapsing-remitting phase, before brain functional reserves are depleted. The remitting-relapsing pattern of alopecia areata, in contrast to the monophasic progressive pattern of androgenic alopecia, is explained. It is proposed that IGF-1, an agent that preserves immune privilege in anagen hair follicles in alopecia areata, also stimulates the regeneration rate of hair follicle cells. Similarly, IFN-&#x003b3;, which disrupts hair follicle immune privilege, also slows the regeneration rate of hair follicle cells. This raises the possibility of a new mechanism that enables the remission-relapse cycles in alopecia areata. An explanation for the differing patterns of experimental autoimmune uveitis&#x02014;either monophasic or remitting-relapsing&#x02014;induced by immunization with two different antigens, is also provided, based on the rate of regeneration.</p></sec></body><back><ack><title>Acknowledgments</title><p>The author would like to acknowledge the assistance of ChatGPT (GPT-4-turbo variant, August 2024 release) in helping with the English editing of this manuscript.</p></ack><sec sec-type="data-availability" id="s7"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>ZE: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>ZE was employed by Taro Pharmaceutical Industries Ltd.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that Generative AI was used in the creation of this manuscript. Generative AI was used for English editing of this manuscript [ChatGPT (GPT-4-turbo variant, August 2024 release).</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="disclaimer" id="s13"><title>Author disclaimer</title><p>The views and opinions expressed, and/or conclusions drawn, in this article are those of the author and do not necessarily reflect those of Taro Pharmaceutical Industries Ltd., its affiliates, directors or employees.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lebel</surname><given-names>Y</given-names></name><name><surname>Milo</surname><given-names>T</given-names></name><name><surname>Bar</surname><given-names>A</given-names></name><name><surname>Mayo</surname><given-names>A</given-names></name><name><surname>Alon</surname><given-names>U</given-names></name></person-group>. <article-title>Excitable dynamics of flares and relapses in autoimmune diseases</article-title>. <source>iScience.</source> (<year>2023</year>) <volume>26</volume>:<elocation-id>108084</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.isci.2023.108084</pub-id>
<pub-id pub-id-type="pmid">37915612</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Herrath</surname><given-names>M</given-names></name><name><surname>Sanda</surname><given-names>S</given-names></name><name><surname>Herold</surname><given-names>K</given-names></name></person-group>. <article-title>Type 1 diabetes as a relapsing-remitting disease</article-title>? <source>Nat Rev Immunol</source>. (<year>2007</year>) <volume>7</volume>:<page-range>988&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri2192</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Filippi</surname><given-names>M</given-names></name><name><surname>Bar-Or</surname><given-names>A</given-names></name><name><surname>Piehl</surname><given-names>F</given-names></name><name><surname>Preziosa</surname><given-names>P</given-names></name><name><surname>Solari</surname><given-names>A</given-names></name><name><surname>Vukusic</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Multiple sclerosis</article-title>. <source>Nat Rev Dis Primers.</source> (<year>2018</year>) <volume>4</volume>:<fpage>43</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41572-018-0050-3</pub-id>
<pub-id pub-id-type="pmid">30410033</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willems</surname><given-names>JIA</given-names></name><name><surname>van Twist</surname><given-names>DJL</given-names></name><name><surname>Peeters</surname><given-names>RP</given-names></name><name><surname>Mostard</surname><given-names>GJM</given-names></name><name><surname>van Wijngaarden</surname><given-names>RFATL</given-names></name></person-group>. <article-title>Stress-induced graves disease: spontaneous recovery after stress relief</article-title>. <source>J Endocr Soc</source>. (<year>2023</year>) <volume>8</volume>:<elocation-id>bvad157</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1210/jendso/bvad157</pub-id>
<pub-id pub-id-type="pmid">38148855</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Toerne</surname><given-names>C</given-names></name><name><surname>Sieg</surname><given-names>C</given-names></name><name><surname>Kaufmann</surname><given-names>U</given-names></name><name><surname>Diedrichs-M&#x000f6;hring</surname><given-names>M</given-names></name><name><surname>Nelson</surname><given-names>PJ</given-names></name><name><surname>Wildner</surname><given-names>G</given-names></name></person-group>. <article-title>Effector T cells driving monophasic vs. relapsing/remitting experimental autoimmune uveitis show unique pathway signatures</article-title>. <source>Mol Immunol</source>. (<year>2010</year>) <volume>48</volume>:<page-range>272&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.molimm.2010.07.017</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkoshi</surname><given-names>Z</given-names></name></person-group>. <article-title>Autoimmune diseases refractory to corticosteroids and immunosuppressants</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1447337</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1447337</pub-id>
<pub-id pub-id-type="pmid">39351223</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rodrigues Oliveira</surname><given-names>SM</given-names></name><name><surname>Rebocho</surname><given-names>A</given-names></name><name><surname>Ahmadpour</surname><given-names>E</given-names></name><name><surname>Nissapatorn</surname><given-names>V</given-names></name><name><surname>de Lourdes Pereira</surname><given-names>M</given-names></name></person-group>. <article-title>Type 1 diabetes mellitus: A review on advances and challenges in creating insulin producing devices</article-title>. <source>Micromachines (Basel).</source> (<year>2023</year>) <volume>14</volume>:<elocation-id>151</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/mi14010151</pub-id>
<pub-id pub-id-type="pmid">36677212</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Melton</surname><given-names>DA</given-names></name></person-group>. <article-title>Pancreas regeneration</article-title>. <source>Nature.</source> (<year>2018</year>) <volume>557</volume>:<page-range>351&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-018-0294-9</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agner</surname><given-names>T</given-names></name><name><surname>Damm</surname><given-names>P</given-names></name><name><surname>Binder</surname><given-names>C</given-names></name></person-group>. <article-title>Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients</article-title>. <source>Diabetes Care</source>. (<year>1987</year>) <volume>10</volume>:<page-range>164&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2337/diacare.10.2.164</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jane&#x0017e;</surname><given-names>A</given-names></name><name><surname>Guja</surname><given-names>C</given-names></name><name><surname>Mitrakou</surname><given-names>A</given-names></name><name><surname>Lalic</surname><given-names>N</given-names></name><name><surname>Tankova</surname><given-names>T</given-names></name><name><surname>Czupryniak</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Insulin therapy in adults with type 1 diabetes mellitus: a narrative review</article-title>. <source>Diabetes Ther</source>. (<year>2020</year>) <volume>11</volume>:<fpage>387</fpage>&#x02013;<lpage>409</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s13300-019-00743-7</pub-id>
<pub-id pub-id-type="pmid">31902063</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>CH</given-names></name><name><surname>Sood</surname><given-names>T</given-names></name><name><surname>Zito</surname><given-names>PM</given-names></name></person-group>. <article-title>Androgenetic alopecia</article-title>. In: <source>StatPearls</source>. <publisher-name>StatPearls Publishing</publisher-name>, <publisher-loc>Treasure Island (FL</publisher-loc> (<year>2024</year>). Available at: <uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK430924/">https://www.ncbi.nlm.nih.gov/books/NBK430924/</uri>.</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Hamada</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Itami</surname><given-names>S</given-names></name></person-group>. <article-title>Expression of mRNA for androgen receptor, 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase in human dermal papilla cells</article-title>. <source>Br J Dermatol</source>. (<year>1999</year>) <volume>141</volume>:<page-range>840&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1046/j.1365-2133.1999.03156.x</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hibberts</surname><given-names>NA</given-names></name><name><surname>Howell</surname><given-names>AE</given-names></name><name><surname>Randall</surname><given-names>VA</given-names></name></person-group>. <article-title>Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp</article-title>. <source>J Endocrinol</source>. (<year>1998</year>) <volume>156</volume>:<fpage>59</fpage>&#x02013;<lpage>65</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1677/joe.0.1560059</pub-id>
<pub-id pub-id-type="pmid">9496234</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choudhry</surname><given-names>R</given-names></name><name><surname>Hodgins</surname><given-names>MB</given-names></name><name><surname>van der Kwast</surname><given-names>TH</given-names></name><name><surname>Brinkmann</surname><given-names>AO</given-names></name><name><surname>Boersma</surname><given-names>WJ</given-names></name></person-group>. <article-title>Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands</article-title>. <source>J Endocrinol</source>. (<year>1992</year>) <volume>133</volume>:<page-range>467&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1677/joe.0.1330467</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>JJ</given-names></name><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Lai</surname><given-names>KP</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name></person-group>. <article-title>The role of androgen and androgen receptor in skin-related disorders</article-title>. <source>Arch Dermatol Res</source>. (<year>2012</year>) <volume>304</volume>:<fpage>499</fpage>&#x02013;<lpage>510</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00403-012-1265-x</pub-id>
<pub-id pub-id-type="pmid">22829074</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inui</surname><given-names>S</given-names></name><name><surname>Itami</surname><given-names>S</given-names></name></person-group>. <article-title>Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla</article-title>. <source>J Dermatol Sci</source>. (<year>2011</year>) <volume>61</volume>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jdermsci.2010.10.015</pub-id>
<pub-id pub-id-type="pmid">21167691</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whiting</surname><given-names>DA</given-names></name></person-group>. <article-title>Chronic telogen effluvium: increased scalp hair shedding in middle-aged women</article-title>. <source>J Am Acad Dermatol</source>. (<year>1996</year>) <volume>35</volume>:<fpage>899</fpage>&#x02013;<lpage>906</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0190-9622(96)90113-9</pub-id>
<pub-id pub-id-type="pmid">8959948</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jaworsky</surname><given-names>C</given-names></name><name><surname>Kligman</surname><given-names>AM</given-names></name><name><surname>Murphy</surname><given-names>GF</given-names></name></person-group>. <article-title>Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis</article-title>. <source>Br J Dermatol</source>. (<year>1992</year>) <volume>127</volume>:<page-range>239&#x02013;46</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1365-2133.1992.tb00121.x</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sueki</surname><given-names>H</given-names></name><name><surname>Stoudemayer</surname><given-names>T</given-names></name><name><surname>Kligman</surname><given-names>AM</given-names></name><name><surname>Murphy</surname><given-names>GF</given-names></name></person-group>. <article-title>Quantitative and ultrastructural analysis of inflammatory infiltrates in male pattern alopecia</article-title>. <source>Acta Derm Venereol.</source> (<year>1999</year>) <volume>79</volume>:<page-range>347&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/000155599750010238</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez-Jacobo</surname><given-names>L</given-names></name><name><surname>Ancer-Arellano</surname><given-names>CI</given-names></name><name><surname>Ortiz-Lopez</surname><given-names>R</given-names></name><name><surname>Salinas-Santander</surname><given-names>M</given-names></name><name><surname>Villarreal-Villarreal</surname><given-names>CD</given-names></name><name><surname>Ancer-Rodriguez</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Evaluation of the expression of genes associated with inflammation and apoptosis in androgenetic alopecia by targeted RNA-seq</article-title>. <source>Skin Appendage Disord</source>. (<year>2018</year>) <volume>4</volume>:<page-range>268&#x02013;73</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1159/000484530</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leir&#x000f3;s</surname><given-names>GJ</given-names></name><name><surname>Ceruti</surname><given-names>JM</given-names></name><name><surname>Castellanos</surname><given-names>ML</given-names></name><name><surname>Kusinsky</surname><given-names>AG</given-names></name><name><surname>Bala&#x000f1;&#x000e1;</surname><given-names>ME</given-names></name></person-group>. <article-title>Androgens modify Wnt agonists/antagonists expression balance in dermal papilla cells preventing hair follicle stem cell differentiation in androgenetic alopecia</article-title>. <source>Mol Cell Endocrinol</source>. (<year>2017</year>) <volume>439</volume>:<fpage>26</fpage>&#x02013;<lpage>34</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.mce.2016.10.018</pub-id>
<pub-id pub-id-type="pmid">27769713</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garza</surname><given-names>LA</given-names></name><name><surname>Yang</surname><given-names>CC</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Blatt</surname><given-names>HB</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells</article-title>. <source>J Clin Invest.</source> (<year>2011</year>) <volume>121</volume>:<page-range>613&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1172/JCI44478</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dumont</surname><given-names>JE</given-names></name><name><surname>Lamy</surname><given-names>F</given-names></name><name><surname>Roger</surname><given-names>P</given-names></name><name><surname>Maenhaut</surname><given-names>C</given-names></name></person-group>. <article-title>Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors</article-title>. <source>Physiol Rev</source>. (<year>1992</year>) <volume>72</volume>:<page-range>667&#x02013;97</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1152/physrev.1992.72.3.667</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coclet</surname><given-names>J</given-names></name><name><surname>Foureau</surname><given-names>F</given-names></name><name><surname>Ketelbant</surname><given-names>P</given-names></name><name><surname>Galand</surname><given-names>P</given-names></name><name><surname>Dumont</surname><given-names>JE</given-names></name></person-group>. <article-title>Cell population kinetics in dog and human adult thyroid</article-title>. <source>Clin Endocrinol (Oxf).</source> (<year>1989</year>) <volume>31</volume>:<page-range>655&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1365-2265.1989.tb01290.x</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pustelnik</surname><given-names>FS</given-names></name><name><surname>Gronbek</surname><given-names>C</given-names></name><name><surname>D&#x000f8;ssing</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>N</given-names></name><name><surname>Bonnema</surname><given-names>SJ</given-names></name><name><surname>Heged&#x000fc;s</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The compensatory enlargement of the remaining thyroid lobe following hemithyroidectomy is small and without impact on symptom relief</article-title>. <source>Eur Arch Otorhinolaryngol</source>. (<year>2018</year>) <volume>275</volume>:<page-range>161&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00405-017-4777-3</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chistiakov</surname><given-names>DA</given-names></name></person-group>. <article-title>Immunogenetics of hashimoto&#x02019;s thyroiditis</article-title>. <source>J Autoimmune Dis</source>. (<year>2005</year>) <volume>11(2)</volume>:<elocation-id>1</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/1740-2557-2-1</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takasu</surname><given-names>N</given-names></name><name><surname>Komiya</surname><given-names>I</given-names></name><name><surname>Asawa</surname><given-names>T</given-names></name><name><surname>Nagasawa</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name></person-group>. <article-title>Test for recovery from hypothyroidism during thyroxine therapy in Hashimoto&#x02019;s thyroiditis</article-title>. <source>Lancet.</source> (<year>1990</year>) <volume>336</volume>:<page-range>1084&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/0140-6736(90)92567-2</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Admoni</surname><given-names>O</given-names></name><name><surname>Rath</surname><given-names>S</given-names></name><name><surname>Almagor</surname><given-names>T</given-names></name><name><surname>Elias-Assad</surname><given-names>G</given-names></name><name><surname>Tenenbaum-Rakover</surname><given-names>Y</given-names></name></person-group>. <article-title>Long-term follow-up and outcomes of autoimmune thyroiditis in childhood</article-title>. <source>Front Endocrinol (Lausanne).</source> (<year>2020</year>) <volume>5</volume>:<elocation-id>309</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fendo.2020.00309</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>TF</given-names></name><name><surname>Andersen</surname><given-names>S</given-names></name><name><surname>Latif</surname><given-names>R</given-names></name><name><surname>Nagayama</surname><given-names>Y</given-names></name><name><surname>Barbesino</surname><given-names>G</given-names></name><name><surname>Brito</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Graves&#x02019; disease</article-title>. <source>Nat Rev Dis Primers.</source> (<year>2020</year>) <volume>6</volume>:<fpage>52</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41572-020-0184-y</pub-id>
<pub-id pub-id-type="pmid">32616746</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Codaccioni</surname><given-names>JL</given-names></name><name><surname>Orgiazzi</surname><given-names>J</given-names></name><name><surname>Blanc</surname><given-names>P</given-names></name><name><surname>Pugeat</surname><given-names>M</given-names></name><name><surname>Roulier</surname><given-names>R</given-names></name><name><surname>Carayon</surname><given-names>P</given-names></name></person-group>. <article-title>Lasting remissions in patients treated for Graves&#x02019; hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>1988</year>) <volume>67</volume>:<page-range>656&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1210/jcem-67-4-656</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Peeters</surname><given-names>RP</given-names></name><name><surname>Visser</surname><given-names>T</given-names></name></person-group>. <article-title>Metabolism of thyroid hormone</article-title>. In: <person-group person-group-type="editor"><name><surname>Feingold</surname><given-names>KR</given-names></name><name><surname>Anawalt</surname><given-names>B</given-names></name><name><surname>Blackman</surname><given-names>MR</given-names></name><etal/></person-group>, editors. <source>Endotext</source>. (<year>2000</year>) <publisher-loc>South Dartmouth (MA)</publisher-loc>: <publisher-name>MDText.com, Inc.</publisher-name>. Available at: <uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK285545/">https://www.ncbi.nlm.nih.gov/books/NBK285545/</uri>.</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larsen</surname><given-names>PR</given-names></name><name><surname>Zavacki</surname><given-names>AM</given-names></name></person-group>. <article-title>The role of the iodothyronine deiodinases in the physiology and pathophysiology of thyroid hormone action</article-title>. <source>Eur Thyroid J</source>. (<year>2012</year>) <volume>1</volume>:<page-range>232&#x02013;42</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1159/000343922</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>B</given-names></name></person-group>. <article-title>A guide to the Michaelis-Menten equation: steady state and beyond</article-title>. <source>FEBS J</source>. (<year>2022</year>) <volume>289</volume>:<page-range>6086&#x02013;98</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/febs.16124</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>MM</given-names></name><name><surname>DeLellis</surname><given-names>RA</given-names></name><name><surname>Wolfe</surname><given-names>HJ</given-names></name></person-group>. <article-title>Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment</article-title>. <source>Ann Intern Med</source>. (<year>1997</year>) <volume>126</volume>:<page-range>682&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7326/0003-4819-126-9-199705010-00002</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fonolleda</surname><given-names>M</given-names></name><name><surname>Murillo</surname><given-names>M</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>F</given-names></name><name><surname>Bel</surname><given-names>J</given-names></name><name><surname>Vives-Pi</surname><given-names>M</given-names></name></person-group>. <article-title>Remission phase in pediatric type 1 diabetes: new understanding and emerging biomarkers</article-title>. <source>Horm Res Pediatr</source>. (<year>2017</year>) <volume>88</volume>:<page-range>307&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1159/000479030</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rompolas</surname><given-names>P</given-names></name><name><surname>Greco</surname><given-names>V</given-names></name></person-group>. <article-title>Stem cell dynamics in the hair follicle niche</article-title>. <source>Semin Cell Dev Biol</source>. (<year>2014</year>) <fpage>25</fpage>&#x02013;<lpage>26:34-42</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.semcdb.2013.12.005</pub-id>
<pub-id pub-id-type="pmid">24977333</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Bulfone-Paus</surname><given-names>S</given-names></name><name><surname>Bertolini</surname><given-names>M</given-names></name></person-group>. <article-title>Hair follicle immune privilege revisited: the key to alopecia areata management</article-title>. <source>J Investig Dermatol Symp Proc</source>. (<year>2018</year>) <volume>19</volume>:<page-range>S12&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jisp.2017.10.014</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Huang</surname><given-names>WY</given-names></name><name><surname>Wang</surname><given-names>EHC</given-names></name><name><surname>Tai</surname><given-names>KY</given-names></name><name><surname>Lin</surname><given-names>SJ</given-names></name></person-group>. <article-title>Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunction for hair regeneration</article-title>. <source>J BioMed Sci</source>. (<year>2020</year>) <volume>27</volume>:<fpage>43</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12929-020-0624-8</pub-id>
<pub-id pub-id-type="pmid">32171310</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strazzulla</surname><given-names>LC</given-names></name><name><surname>Wang</surname><given-names>EHC</given-names></name><name><surname>Avila</surname><given-names>L</given-names></name><name><surname>Lo Sicco</surname><given-names>K</given-names></name><name><surname>Brinster</surname><given-names>N</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis</article-title>. <source>J Am Acad Dermatol</source>. (<year>2018</year>) <volume>78</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaad.2017.04.1141</pub-id>
<pub-id pub-id-type="pmid">29241771</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lintzeri</surname><given-names>DA</given-names></name><name><surname>Constantinou</surname><given-names>A</given-names></name><name><surname>Hillmann</surname><given-names>K</given-names></name><name><surname>Ghoreschi</surname><given-names>K</given-names></name><name><surname>Vogt</surname><given-names>A</given-names></name><name><surname>Blume-Peytavi</surname><given-names>U</given-names></name></person-group>. <article-title>Alopecia areata - Current understanding and management</article-title>. <source>J Dtsch Dermatol Ges.</source> (<year>2022</year>) <volume>20</volume>:<fpage>59</fpage>&#x02013;<lpage>90</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/ddg.14689</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group>. <article-title>Deciphering the molecular mechanisms of stem cell dynamics in hair follicle regeneration</article-title>. <source>Exp Mol Med</source>. (<year>2024</year>) <volume>56</volume>:<page-range>110&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s12276-023-01151-5</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahn</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Hahm</surname><given-names>DH</given-names></name></person-group>. <article-title>Psychological stress-induced pathogenesis of alopecia areata: autoimmune and apoptotic pathways</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>20(24)</volume>:<elocation-id>11711</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms241411711</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name></person-group>. <article-title>Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata</article-title>. <source>Clin Dev Immunol</source>. (<year>2013</year>) <volume>2013</volume>:<elocation-id>348546</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2013/348546</pub-id>
<pub-id pub-id-type="pmid">24151515</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breitkopf</surname><given-names>T</given-names></name><name><surname>Lo</surname><given-names>BK</given-names></name><name><surname>Leung</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Carr</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Somatostatin expression in human hair follicles and its potential role in immune privilege</article-title>. <source>J Invest Dermatol</source>. (<year>2013</year>) <volume>133</volume>:<page-range>1722&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/jid.2013.53</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Bettermann</surname><given-names>A</given-names></name><name><surname>Tokura</surname><given-names>Y</given-names></name><name><surname>Takigawa</surname><given-names>M</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group>. <article-title>Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model</article-title>. <source>Am J Pathol</source>. (<year>2004</year>) <volume>164</volume>:<page-range>623&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0002-9440(10)63151-3</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group>. <article-title>Interferon gamma inhibits the differentiation of mouse adult liver and bone marrow hematopoietic stem cells by inhibiting the activation of notch signaling</article-title>. <source>Stem Cell Res Ther</source>. (<year>2019</year>) <volume>10</volume>:<fpage>210</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13287-019-1311-0</pub-id>
<pub-id pub-id-type="pmid">31311586</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name></person-group>. <article-title>Regulation of signaling pathways in hair follicle stem cells</article-title>. <source>Burns Trauma</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>tkac022</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/burnst/tkac022</pub-id>
<pub-id pub-id-type="pmid">35795256</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Youssef</surname><given-names>A</given-names></name><name><surname>Aboalola</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>VK</given-names></name></person-group>. <article-title>The roles of insulin-like growth factors in mesenchymal stem cell niche</article-title>. <source>Stem Cells Int</source>. (<year>2017</year>) <volume>2017</volume>:<elocation-id>9453108</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2017/9453108</pub-id>
<pub-id pub-id-type="pmid">28298931</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>L&#x000f6;hr</surname><given-names>JM</given-names></name><name><surname>Faissner</surname><given-names>R</given-names></name><name><surname>Koczan</surname><given-names>D</given-names></name><name><surname>Bewerunge</surname><given-names>P</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process</article-title>. <source>Am J Gastroenterol</source>. (<year>2010</year>) <volume>105</volume>:<page-range>2060&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ajg.2010.141</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Overbeek</surname><given-names>KA</given-names></name><name><surname>Poulsen</surname><given-names>JL</given-names></name><name><surname>Lanzillotta</surname><given-names>M</given-names></name><name><surname>Vinge-Holmquist</surname><given-names>O</given-names></name><name><surname>Macinga</surname><given-names>P</given-names></name><name><surname>Demirci</surname><given-names>AF</given-names></name><etal/></person-group>. <article-title>Type 1 autoimmune pancreatitis in europe: clinical profile and response to treatment</article-title>. <source>Clin Gastroenterol Hepatol</source>. (<year>2024</year>) <volume>22</volume>:<fpage>994</fpage>&#x02013;<lpage>1004.e10</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cgh.2023.12.010</pub-id>
<pub-id pub-id-type="pmid">38184096</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kubota</surname><given-names>K</given-names></name><name><surname>Iida</surname><given-names>H</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name><name><surname>Inamori</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis</article-title>. <source>Gastrointest Endosc.</source> (<year>2007</year>) <volume>66</volume>:<page-range>1142&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.gie.2007.06.059</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dubrovsky</surname><given-names>G</given-names></name><name><surname>Dunn</surname><given-names>JCY</given-names></name></person-group>. <article-title>Mechanisms for intestinal regeneration</article-title>. <source>Curr Opin Pediatr</source>. (<year>2018</year>) <volume>30</volume>:<page-range>424&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/MOP.0000000000000630</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>JT</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Goyal</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>ZQ</given-names></name><name><surname>Zhang</surname><given-names>JX</given-names></name><etal/></person-group>. <article-title>Diagnostic accuracy of fecal calprotectin for predicting relapse in inflammatory bowel disease: A meta-analysis</article-title>. <source>J Clin Med</source>. (<year>2023</year>) <volume>12</volume>:<elocation-id>1206</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/jcm12031206</pub-id>
<pub-id pub-id-type="pmid">36769850</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baars</surname><given-names>JE</given-names></name><name><surname>Nuij</surname><given-names>VJ</given-names></name><name><surname>Oldenburg</surname><given-names>B</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><name><surname>van der Woude</surname><given-names>CJ</given-names></name></person-group>. <article-title>Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation</article-title>. <source>Inflammation Bowel Dis</source>. (<year>2012</year>) <volume>18</volume>:<page-range>1634&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/ibd.21925</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahad</surname><given-names>DH</given-names></name><name><surname>Trapp</surname><given-names>BD</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Pathological mechanisms in progressive multiple sclerosis</article-title>. <source>Lancet Neurol</source>. (<year>2015</year>) <volume>14</volume>:<page-range>183&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70256-X</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinman</surname><given-names>L</given-names></name></person-group>. <article-title>Immunology of relapse and remission in multiple sclerosis</article-title>. <source>Annu Rev Immunol</source>. (<year>2014</year>) <volume>32</volume>:<page-range>257&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120227</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeller</surname><given-names>D</given-names></name><name><surname>Classen</surname><given-names>J</given-names></name></person-group>. <article-title>Plasticity of the motor system in multiple sclerosis</article-title>. <source>Neuroscience.</source> (<year>2014</year>) <volume>283</volume>:<page-range>222&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.05.043</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>H</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Arnoutelis</surname><given-names>R</given-names></name><name><surname>Jenkinson</surname><given-names>M</given-names></name><name><surname>Antel</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><etal/></person-group>. <article-title>Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis</article-title>. <source>Brain.</source> (<year>2000</year>) <volume>123 </volume>:<page-range>2314&#x02013;20</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/brain/123.11.2314</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkoshi</surname><given-names>Z</given-names></name></person-group>. <article-title>The binary classification of chronic diseases</article-title>. <source>J Inflammation Res</source>. (<year>2019</year>) <volume>12</volume>:<page-range>319&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/JIR.S227279</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Athanassiou</surname><given-names>L</given-names></name><name><surname>Mavragani</surname><given-names>CP</given-names></name><name><surname>Koutsilieris</surname><given-names>M</given-names></name></person-group>. <article-title>The immunomodulatory properties of vitamin D</article-title>. <source>Mediterr J Rheumatol</source>. (<year>2022</year>) <volume>33</volume>:<fpage>7</fpage>&#x02013;<lpage>13</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.31138/mjr.33.1.7</pub-id>
<pub-id pub-id-type="pmid">35611096</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkoshi</surname><given-names>Z</given-names></name></person-group>. <article-title>TGF-&#x003b2;, IL-1&#x003b2;, IL-6 levels and TGF-&#x003b2;/Smad pathway reactivity regulate the link between allergic diseases, cancer risk, and metabolic dysregulations</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1371753</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1371753</pub-id>
<pub-id pub-id-type="pmid">38629073</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bar-Or</surname><given-names>A</given-names></name></person-group>. <article-title>The immunology of multiple sclerosis</article-title>. <source>Semin Neurol</source>. (<year>2008</year>) <volume>28</volume>:<fpage>29</fpage>&#x02013;<lpage>45</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1055/s-2007-1019124</pub-id>
<pub-id pub-id-type="pmid">18256985</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quintana</surname><given-names>FJ</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Yeste</surname><given-names>A</given-names></name><name><surname>Nyirenda</surname><given-names>M</given-names></name><name><surname>Kenison</surname><given-names>J</given-names></name><name><surname>Rahbari</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Canadian Pediatric Demyelinating Disease Network. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis</article-title>. <source>Neurology.</source> (<year>2014</year>) <volume>83</volume>:<page-range>2219&#x02013;26</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1212/WNL.0000000000001066</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Abduljabbar</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Osier</surname><given-names>N</given-names></name></person-group>. <article-title>The relationship between stress and disease onset and relapse in multiple sclerosis: A systematic review</article-title>. <source>Mult Scler Relat Disord</source>. (<year>2022</year>) <volume>67</volume>:<elocation-id>104142</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.msard.2022.104142</pub-id>
<pub-id pub-id-type="pmid">36155965</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dhabhar</surname><given-names>FS</given-names></name></person-group>. <article-title>Effects of stress on immune function: the good, the bad, and the beautiful</article-title>. <source>Immunol Res</source>. (<year>2014</year>) <volume>58</volume>:<fpage>193</fpage>&#x02013;<lpage>210</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12026-014-8517-0</pub-id>
<pub-id pub-id-type="pmid">24798553</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merkler</surname><given-names>D</given-names></name><name><surname>Ernsting</surname><given-names>T</given-names></name><name><surname>Kerschensteiner</surname><given-names>M</given-names></name><name><surname>Br&#x000fc;ck</surname><given-names>W</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name></person-group>. <article-title>A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination</article-title>. <source>Brain.</source> (<year>2006</year>) <volume>129</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/brain/awl135</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petersen</surname><given-names>AM</given-names></name><name><surname>Pedersen</surname><given-names>BK</given-names></name></person-group>. <article-title>The anti-inflammatory effect of exercise</article-title>. <source>J Appl Physiol (1985).</source> (<year>2005</year>) <volume>98</volume>:<page-range>1154&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1152/japplphysiol.00164.2004</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spadaro</surname><given-names>M</given-names></name><name><surname>Amendolea</surname><given-names>MA</given-names></name><name><surname>Mazzucconi</surname><given-names>MG</given-names></name><name><surname>Fantozzi</surname><given-names>R</given-names></name><name><surname>Di Lello</surname><given-names>R</given-names></name><name><surname>Zangari</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies</article-title>. <source>Mult Scler.</source> (<year>1999</year>) <volume>5</volume>:<page-range>121&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/135245859900500209</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rocca</surname><given-names>MA</given-names></name><name><surname>Ceccarelli</surname><given-names>A</given-names></name><name><surname>Rodegher</surname><given-names>M</given-names></name><name><surname>Misci</surname><given-names>P</given-names></name><name><surname>Riccitelli</surname><given-names>G</given-names></name><name><surname>Falini</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Preserved brain adaptive properties in patients with benign multiple sclerosis</article-title>. <source>Neurology.</source> (<year>2010</year>) <volume>74</volume>:<page-range>142&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c91a00</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tyler</surname><given-names>KL</given-names></name></person-group>. <article-title>The enigmatic links between Epstein-Barr virus infection and multiple sclerosis</article-title>. <source>J Clin Invest.</source> (<year>2022</year>) <volume>132</volume>:<fpage>e160468</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1172/JCI160468</pub-id>
<pub-id pub-id-type="pmid">35499072</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maple</surname><given-names>PA</given-names></name><name><surname>Ascherio</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>Cutter</surname><given-names>G</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Shannon-Lowe</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The potential for EBV vaccines to prevent multiple sclerosis</article-title>. <source>Front Neurol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>887794</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fneur.2022.887794</pub-id>
<pub-id pub-id-type="pmid">35812097</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>P</given-names></name><name><surname>Dorstyn</surname><given-names>DS</given-names></name><name><surname>Prior</surname><given-names>E</given-names></name></person-group>. <article-title>Stress management interventions for multiple sclerosis: A meta-analysis of randomized controlled trials</article-title>. <source>J Health Psychol</source>. (<year>2020</year>) <volume>25</volume>:<page-range>266&#x02013;79</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/1359105319860185</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Negaresh</surname><given-names>R</given-names></name><name><surname>Motl</surname><given-names>RW</given-names></name><name><surname>Zimmer</surname><given-names>P</given-names></name><name><surname>Mokhtarzade</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>JS</given-names></name></person-group>. <article-title>Effects of exercise training on multiple sclerosis biomarkers of central nervous system and disease status: a systematic review of intervention studies</article-title>. <source>Eur J Neurol</source>. (<year>2019</year>) <volume>26</volume>:<page-range>711&#x02013;21</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/ene.13929</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kj&#x000f8;lhede</surname><given-names>T</given-names></name><name><surname>Siemonsen</surname><given-names>S</given-names></name><name><surname>Wenzel</surname><given-names>D</given-names></name><name><surname>Stellmann</surname><given-names>JP</given-names></name><name><surname>Ringgaard</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>BG</given-names></name><etal/></person-group>. <article-title>Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis</article-title>? <source>Mult Scler</source>. (<year>2018</year>) <volume>24</volume>:<page-range>1356&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/1352458517722645</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Learmonth</surname><given-names>YC</given-names></name><name><surname>Motl</surname><given-names>RW</given-names></name></person-group>. <article-title>Exercise training for multiple sclerosis: A narrative review of history, benefits, safety, guidelines, and promotion</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2021</year>) <volume>18</volume>:<elocation-id>13245</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijerph182413245</pub-id>
<pub-id pub-id-type="pmid">34948854</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shome</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>Y</given-names></name><name><surname>Chavan</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>LaBaer</surname><given-names>J</given-names></name></person-group>. <article-title>Serum autoantibodyome reveals that healthy individuals share common autoantibodies</article-title>. <source>Cell Rep</source>. (<year>2022</year>) <volume>39</volume>:<elocation-id>110873</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.celrep.2022.110873</pub-id>
<pub-id pub-id-type="pmid">35649350</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ge</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Antinuclear antibodies in healthy population: Positive association with abnormal tissue metabolism, inflammation and immune dysfunction</article-title>. <source>Int Immunopharmacol</source>. (<year>2022</year>) <volume>113</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.intimp.2022.109292</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Feltkamp</surname><given-names>TE</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><name><surname>Butcher</surname><given-names>B</given-names></name><name><surname>Dawkins</surname><given-names>R</given-names></name><name><surname>Fritzler</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Range of antinuclear antibodies in &#x0201c;healthy&#x0201d; individuals</article-title>. <source>Arthritis Rheumatol</source>. (<year>1997</year>) <volume>40</volume>:<page-range>1601&#x02013;11</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/art.1780400909</pub-id>
</mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hil&#x000e1;rio</surname><given-names>MO</given-names></name><name><surname>Len</surname><given-names>CA</given-names></name><name><surname>Roja</surname><given-names>SC</given-names></name><name><surname>Terreri</surname><given-names>MT</given-names></name><name><surname>Almeida</surname><given-names>G</given-names></name><name><surname>Andrade</surname><given-names>LE</given-names></name></person-group>. <article-title>Frequency of antinuclear antibodies in healthy children and adolescents</article-title>. <source>Clin Pediatr (Phila).</source> (<year>2004</year>) <volume>43</volume>:<page-range>637&#x02013;42</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/000992280404300709</pub-id>
</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagele</surname><given-names>EP</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Acharya</surname><given-names>NK</given-names></name><name><surname>DeMarshall</surname><given-names>C</given-names></name><name><surname>Kosciuk</surname><given-names>MC</given-names></name><name><surname>Nagele</surname><given-names>RG</given-names></name></person-group>. <article-title>Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e60726</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0060726</pub-id>
<pub-id pub-id-type="pmid">23589757</pub-id>
</mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griffin</surname><given-names>DO</given-names></name><name><surname>Holodick</surname><given-names>NE</given-names></name><name><surname>Rothstein</surname><given-names>TL</given-names></name></person-group>. <article-title>Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-</article-title>. <source>J Exp Med</source>. (<year>2011</year>) <volume>208</volume>:<fpage>67</fpage>&#x02013;<lpage>80</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1084/jem.20101499</pub-id>
<pub-id pub-id-type="pmid">21220451</pub-id>
</mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>W</given-names></name><name><surname>Lakkis</surname><given-names>FG</given-names></name><name><surname>Cells</surname><given-names>CGB</given-names></name></person-group>. <article-title>Antibodies, and more</article-title>. <source>Clin J Am Soc Nephrol.</source> (<year>2016</year>) <volume>11</volume>:<page-range>137&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2215/CJN.09430915</pub-id>
</mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkon</surname><given-names>K</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name></person-group>. <article-title>Nature and functions of autoantibodies</article-title>. <source>Nat Clin Pract Rheumatol</source>. (<year>2008</year>) <volume>4</volume>:<page-range>491&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncprheum0895</pub-id>
</mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name></person-group>. <article-title>Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes</article-title>? <source>Diabetologia</source>. (<year>2020</year>) <volume>63</volume>:<page-range>1665&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00125-020-05175-8</pub-id>
</mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tandhanand-Banchuin</surname><given-names>N</given-names></name><name><surname>Vannasaeng</surname><given-names>S</given-names></name><name><surname>Ploybutr</surname><given-names>S</given-names></name><name><surname>Sriussadaporn</surname><given-names>S</given-names></name></person-group>. <article-title>Comparison of anti-human insulin antibodies detection by commercial enzyme-linked immunosorbent assay kit, displacement enzyme-linked immunosorbent assay and radioimmunoassay, in Thai diabetic patients</article-title>. <source>Diabetes Res Clin Pract</source>. (<year>1993</year>) <volume>22</volume>:<fpage>71</fpage>&#x02013;<lpage>82</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/0168-8227(93)90134-q</pub-id>
<pub-id pub-id-type="pmid">8137719</pub-id>
</mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heneberg</surname><given-names>P</given-names></name><name><surname>&#x00160;im&#x0010d;&#x000ed;kov&#x000e1;</surname><given-names>D</given-names></name><name><surname>&#x0010c;ech&#x000e1;kov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Ryp&#x000e1;&#x0010d;kov&#x000e1;</surname><given-names>B</given-names></name><name><surname>Ku&#x0010d;era</surname><given-names>P</given-names></name><name><surname>And&#x0011b;l</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Autoantibodies against ZnT8 are rare in Central-European LADA patients and absent in MODY patients, including those positive for other autoantibodies</article-title>. <source>J Diabetes Complications.</source> (<year>2019</year>) <volume>33</volume>(<issue>1</issue>):<fpage>46</fpage>&#x02013;<lpage>52</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jdiacomp.2018.10.004</pub-id>
<pub-id pub-id-type="pmid">30377089</pub-id>
</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese</article-title>. <source>Diabetes Metab Res Rev</source>. (<year>2010</year>) <volume>26</volume>:<page-range>579&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/dmrr.1128</pub-id>
</mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zaharieva</surname><given-names>ET</given-names></name><name><surname>Velikova</surname><given-names>TV</given-names></name><name><surname>Tsakova</surname><given-names>AD</given-names></name><name><surname>Kamenov</surname><given-names>ZA</given-names></name></person-group>. <article-title>Prevalence of positive diabetes-associated autoantibodies among type 2 diabetes and related metabolic and inflammatory differences in a sample of the Bulgarian population</article-title>. <source>J Diabetes Res</source>. (<year>2017</year>) <volume>2017</volume>:<elocation-id>9016148</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2017/9016148</pub-id>
<pub-id pub-id-type="pmid">28573146</pub-id>
</mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mendis</surname><given-names>T</given-names></name><name><surname>Filipova</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Pietropaolo</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>MW</given-names></name></person-group>. <article-title>Affinity purification of serum-derived anti-IA-2 autoantibodies in type 1 diabetes using a novel MBP-IA-2 fusion protein</article-title>. <source>Biochem Biophys Rep</source>. (<year>2022</year>) <volume>33</volume>:<elocation-id>101413</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbrep.2022.101413</pub-id>
<pub-id pub-id-type="pmid">36578528</pub-id>
</mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>I</given-names></name><name><surname>Weets</surname><given-names>I</given-names></name><name><surname>Asanghanwa</surname><given-names>M</given-names></name><name><surname>Ruige</surname><given-names>J</given-names></name><name><surname>Van Gaal</surname><given-names>L</given-names></name><name><surname>Mathieu</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Belgian Diabetes Registry. Contribution of antibodies against IA-2&#x003b2; and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age</article-title>. <source>Diabetes Care</source>. (<year>2011</year>) <volume>34</volume>:<page-range>1760&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2337/dc10-2268</pub-id>
</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>KA</given-names></name><name><surname>Tombs</surname><given-names>MA</given-names></name><name><surname>Christie</surname><given-names>MR</given-names></name></person-group>. <article-title>Autoimmunity to tetraspanin-7 in type 1 diabetes</article-title>. <source>Med Microbiol Immunol</source>. (<year>2020</year>) <volume>209</volume>:<page-range>437&#x02013;45</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00430-020-00674-2</pub-id>
</mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>KA</given-names></name><name><surname>Richardson</surname><given-names>CC</given-names></name><name><surname>Ravishankar</surname><given-names>A</given-names></name><name><surname>Brigatti</surname><given-names>C</given-names></name><name><surname>Liberati</surname><given-names>D</given-names></name><name><surname>Lampasona</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes</article-title>. <source>Diabetes.</source> (<year>2016</year>) <volume>65</volume>:<page-range>1690&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2337/db15-1058</pub-id>
</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petruzelkova</surname><given-names>L</given-names></name><name><surname>Ananieva-Jordanova</surname><given-names>R</given-names></name><name><surname>Vcelakova</surname><given-names>J</given-names></name><name><surname>Vesely</surname><given-names>Z</given-names></name><name><surname>Stechova</surname><given-names>K</given-names></name><name><surname>Lebl</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of Type 1 diabetes mellitus</article-title>. <source>Diabetes Med</source>. (<year>2014</year>) <volume>31</volume>:<page-range>165&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/dme.12308</pub-id>
</mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Mincer</surname><given-names>DL</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group>. <article-title>Hashimoto thyroiditis</article-title>. In: <source>StatPearls</source>. <publisher-name>StatPearls Publishing</publisher-name>, <publisher-loc>Treasure Island (FL</publisher-loc> (<year>2023</year>). Available at.</mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jo</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>DJ</given-names></name></person-group>. <article-title>Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer</article-title>. <source>Korean J Intern Med</source>. (<year>2018</year>) <volume>33</volume>:<page-range>1050&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3904/kjim.2018.289</pub-id>
</mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohno</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>F</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Niimi</surname><given-names>H</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Hosoya</surname><given-names>T</given-names></name></person-group>. <article-title>Anti-thyroid peroxidase antibodies in sera from healthy subjects and from patients with chronic thyroiditis: differences in the ability to inhibit thyroid peroxidase activities</article-title>. <source>Clin Exp Immunol</source>. (<year>1991</year>) <volume>85</volume>:<page-range>459&#x02013;63</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1365-2249.1991.tb05749.x</pub-id>
</mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Kronenberg</surname><given-names>HM</given-names></name><name><surname>Larsen</surname><given-names>PR</given-names></name><name><surname>Melmed</surname><given-names>S</given-names></name><name><surname>Polonsky</surname><given-names>KS</given-names></name></person-group>. <source>Textbook of endocrinology</source>. <edition>11th</edition>. (<year>2008</year>) <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Saunders/Elsevier</publisher-name>. p. <page-range>324&#x02013;5</page-range>.</mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sabeena</surname><given-names>S</given-names></name><name><surname>Anjali</surname><given-names>SABS</given-names></name><name><surname>Poulose</surname><given-names>PK</given-names></name></person-group>. <article-title>Prevalence of thyroid autoantibodies in young asymptomatic females: A pilot study</article-title>. <source>Thyroid Res Pract</source>. (<year>2012</year>) <volume>9</volume>:<fpage>9</fpage>&#x02013;<lpage>11</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4103/0973-0354.92389</pub-id>
</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diana</surname><given-names>T</given-names></name><name><surname>Krause</surname><given-names>J</given-names></name><name><surname>Olivo</surname><given-names>PD</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>J</given-names></name><name><surname>Kanitz</surname><given-names>M</given-names></name><name><surname>Decallonne</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease</article-title>. <source>Clin Exp Immunol</source>. (<year>2017</year>) <volume>189</volume>:<page-range>304&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/cei.12980</pub-id>
</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colapietro</surname><given-names>F</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Generali</surname><given-names>E</given-names></name></person-group>. <article-title>Antimitochondrial antibodies: from bench to bedside</article-title>. <source>Clin Rev Allergy Immunol</source>. (<year>2022</year>) <volume>63</volume>:<page-range>166&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12016-021-08904-y</pub-id>
</mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duda</surname><given-names>S</given-names></name><name><surname>Witte</surname><given-names>T</given-names></name><name><surname>Stangel</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>RE</given-names></name><name><surname>Baerlecken</surname><given-names>NT</given-names></name></person-group>. <article-title>Autoantibodies binding to stathmin-4: new marker for polyneuropathy in primary Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Immunol Res</source>. (<year>2017</year>) <volume>65</volume>:<page-range>1099&#x02013;102</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12026-017-8970-7</pub-id>
</mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orent</surname><given-names>W</given-names></name><name><surname>Mchenry</surname><given-names>AR</given-names></name><name><surname>Rao</surname><given-names>DA</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>HU</given-names></name><name><surname>Bassil</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4+ T cells</article-title>. <source>Hum Mol Genet</source>. (<year>2016</year>) <volume>25</volume>:<page-range>404&#x02013;17</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/hmg/ddv474</pub-id>
</mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frosteg&#x000e5;rd</surname><given-names>J</given-names></name><name><surname>Hellstr&#x000f6;m</surname><given-names>C</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Frosteg&#x000e5;rd</surname><given-names>AG</given-names></name><name><surname>Ajeganova</surname><given-names>S</given-names></name></person-group>. <article-title>Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus</article-title>. <source>Lupus.</source> (<year>2018</year>) <volume>27</volume>:<page-range>1670&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/0961203318788153</pub-id>
</mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>S&#x000e1;nchez Casta&#x000f1;&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Zuliani</surname><given-names>V</given-names></name><name><surname>Amodio</surname><given-names>A</given-names></name><name><surname>Campagnola</surname><given-names>P</given-names></name><name><surname>Granato</surname><given-names>A</given-names></name><name><surname>Gabbrielli</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Role of amylase-&#x003b1;2A autoantibodies in the diagnosis of autoimmune pancreatitis</article-title>. <source>Pancreas.</source> (<year>2015</year>) <volume>44</volume>:<page-range>1078&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/MPA.0000000000000417</pub-id>
</mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tobin</surname><given-names>DJ</given-names></name><name><surname>Orentreich</surname><given-names>N</given-names></name><name><surname>Fenton</surname><given-names>DA</given-names></name><name><surname>Bystryn</surname><given-names>JC</given-names></name></person-group>. <article-title>Antibodies to hair follicles in alopecia areata</article-title>. <source>J Invest Dermatol</source>. (<year>1994</year>) <volume>102</volume>:<page-range>721&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/1523-1747.ep12375477</pub-id>
</mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaertner</surname><given-names>S</given-names></name><name><surname>de Graaf</surname><given-names>KL</given-names></name><name><surname>Greve</surname><given-names>B</given-names></name><name><surname>Weissert</surname><given-names>R</given-names></name></person-group>. <article-title>Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis</article-title>. <source>Neurology.</source> (<year>2004</year>) <volume>63</volume>:<page-range>2381&#x02013;3</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1212/01.wnl.0000147259.34163.33</pub-id>
</mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>Reindl</surname><given-names>M</given-names></name><name><surname>O&#x02019;Reilly</surname><given-names>EJ</given-names></name><name><surname>Levin</surname><given-names>LI</given-names></name><name><surname>Berger</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults</article-title>. <source>Neurology.</source> (<year>2008</year>) <volume>71</volume>:<page-range>1142&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1212/01.wnl.0000316195.52001.e1</pub-id>
</mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hedegaard</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Sellebjerg</surname><given-names>F</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>PS</given-names></name><name><surname>Leslie</surname><given-names>RG</given-names></name><name><surname>Bendtzen</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP</article-title>. <source>Immunology.</source> (<year>2009</year>) <volume>128</volume>:<page-range>e451&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.02999.x</pub-id>
</mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Okazaki</surname><given-names>K</given-names></name><name><surname>Konishi</surname><given-names>Y</given-names></name><name><surname>Ohana</surname><given-names>M</given-names></name><name><surname>Takakuwa</surname><given-names>H</given-names></name><name><surname>Hajiro</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Clinical analysis of autoimmune-related pancreatitis</article-title>. <source>Am J Gastroenterol</source>. (<year>2000</year>) <volume>95</volume>(<issue>10</issue>):<page-range>2788&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.03187.x</pub-id>
</mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Ohana</surname><given-names>M</given-names></name><name><surname>Nakase</surname><given-names>H</given-names></name><name><surname>Uose</surname><given-names>S</given-names></name><name><surname>Inai</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response</article-title>. <source>Gastroenterology.</source> (<year>2000</year>) <volume>118</volume>:<page-range>573&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0016-5085(00)70264-2</pub-id>
</mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teubner</surname><given-names>A</given-names></name><name><surname>Tillmann</surname><given-names>HL</given-names></name><name><surname>Schuppan</surname><given-names>D</given-names></name><name><surname>Gericke</surname><given-names>G</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>St&#x000f6;lzel</surname><given-names>U</given-names></name></person-group>. <article-title>Pr&#x000e4;valenz von zirkulierenden Autoantik&#x000f6;rpern bei gesunden Individuen [Prevalence of circulating autoantibodies in healthy individuals</article-title>. <source>Med Klin (Munich).</source> (<year>2002</year>) <volume>15(97)</volume>:<page-range>645&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00063-002-1207-z</pub-id>
</mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>A</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name></person-group>. <article-title>What determines the regenerative capacity in animals</article-title>? <source>BioScience</source>. (<year>2016</year>) <volume>66</volume>:<page-range>735&#x02013;46</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/biosci/biw079</pub-id>
</mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leblond</surname><given-names>CP</given-names></name></person-group>. <article-title>Classification of cell populations on the basis of their proliferative behavior</article-title>. <source>Natl Cancer Inst Monogr</source>. (<year>1964</year>) <volume>14</volume>:<page-range>119&#x02013;50</page-range>.</mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iismaa</surname><given-names>SE</given-names></name><name><surname>Kaidonis</surname><given-names>X</given-names></name><name><surname>Nicks</surname><given-names>AM</given-names></name><name><surname>Bogush</surname><given-names>N</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Naqvi</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Comparative regenerative mechanisms across different mammalian tissues</article-title>. <source>NPJ Regener Med</source>. (<year>2018</year>) <volume>3</volume>:<elocation-id>6</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41536-018-0044-5</pub-id>
</mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raven</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>WY</given-names></name><name><surname>Man</surname><given-names>TY</given-names></name><name><surname>Ferreira-Gonzalez</surname><given-names>S</given-names></name><name><surname>O&#x02019;Duibhir</surname><given-names>E</given-names></name><name><surname>Dwyer</surname><given-names>BJ</given-names></name><etal/></person-group>. <article-title>Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration</article-title>. <source>Nature.</source> (<year>2017</year>) <volume>547</volume>(<issue>7663</issue>):<page-range>350&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nature23015</pub-id>
</mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diedrichs-M&#x000f6;hring</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Wildner</surname><given-names>G</given-names></name></person-group>. <article-title>Antigen-dependent monophasic or recurrent autoimmune uveitis in rats</article-title>. <source>Int Immunol</source>. (<year>2008</year>) <volume>20</volume>:<page-range>365&#x02013;74</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/intimm/dxm148</pub-id>
</mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stern</surname><given-names>JH</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Funderburgh</surname><given-names>J</given-names></name><name><surname>Pellegrini</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Goldberg</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Regenerating eye tissues to preserve and restore vision</article-title>. <source>Cell Stem Cell</source>. (<year>2018</year>) <volume>22</volume>:<page-range>834&#x02013;49</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.stem.2018.05.013</pub-id>
</mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kallifatidis</surname><given-names>G</given-names></name><name><surname>Mamouni</surname><given-names>K</given-names></name><name><surname>Lokeshwar</surname><given-names>BL</given-names></name></person-group>. <article-title>The role of &#x003b2;-arrestins in regulating stem cell phenotypes in normal and tumorigenic cells</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<elocation-id>9310</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms21239310</pub-id>
<pub-id pub-id-type="pmid">33297302</pub-id>
</mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Jiao</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity</article-title>. <source>Invest Ophthalmol Vis Sci</source>. (<year>2011</year>) <volume>52</volume>:<page-range>3143&#x02013;52</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1167/iovs.10-6334</pub-id>
</mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tasso</surname><given-names>R</given-names></name><name><surname>Ilengo</surname><given-names>C</given-names></name><name><surname>Quarto</surname><given-names>R</given-names></name><name><surname>Cancedda</surname><given-names>R</given-names></name><name><surname>Caspi</surname><given-names>RR</given-names></name><name><surname>Pennesi</surname><given-names>G</given-names></name></person-group>. <article-title>Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis</article-title>. <source>Invest Ophthalmol Vis Sci</source>. (<year>2012</year>) <volume>53</volume>:<page-range>786&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1167/iovs.11-8211</pub-id>
</mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>RJ</given-names></name><name><surname>Rother</surname><given-names>KI</given-names></name></person-group>. <article-title>Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data</article-title>. <source>Pediatr Diabetes.</source> (<year>2008</year>) <volume>9</volume>(<issue>3 Pt 2</issue>):<page-range>14&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1399-5448.2007.00272.x</pub-id>
</mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vanderlugt</surname><given-names>CL</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name></person-group>. <article-title>Epitope spreading in immune-mediated diseases: implications for immunotherapy</article-title>. <source>Nat Rev Immunol</source>. (<year>2002</year>) <volume>2</volume>:<fpage>85</fpage>&#x02013;<lpage>95</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri724</pub-id>
<pub-id pub-id-type="pmid">11910899</pub-id>
</mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Scirpoli</surname><given-names>M</given-names></name><name><surname>Kredel</surname><given-names>K</given-names></name><name><surname>F&#x000fc;chtenbusch</surname><given-names>M</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name></person-group>. <article-title>Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation</article-title>. <source>J Immunol</source>. (<year>1999</year>) <volume>163</volume>:<page-range>525&#x02013;32</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.163.1.525</pub-id>
</mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Tuohy</surname><given-names>VK</given-names></name></person-group>. <article-title>A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease</article-title>. <source>J Exp Med</source>. (<year>1996</year>) <volume>183</volume>:<page-range>1777&#x02013;88</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1084/jem.183.4.1777</pub-id>
</mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boldison</surname><given-names>J</given-names></name><name><surname>Khera</surname><given-names>TK</given-names></name><name><surname>Copland</surname><given-names>DA</given-names></name><name><surname>Stimpson</surname><given-names>ML</given-names></name><name><surname>Crawford</surname><given-names>GL</given-names></name><name><surname>Dick</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis</article-title>. <source>Immunology.</source> (<year>2015</year>) <volume>146</volume>:<page-range>301&#x02013;11</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/imm.12503</pub-id>
</mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sogbein</surname><given-names>O</given-names></name><name><surname>Kochar</surname><given-names>T</given-names></name><name><surname>Afrouzian</surname><given-names>M</given-names></name></person-group>. <article-title>Epitope spreading: the underlying mechanism for combined membranous lupus nephritis and anti-GBM disease</article-title>? <source>Case Rep Nephrol</source>. (<year>2023</year>) <volume>24</volume>:<fpage>2023:3190042</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2023/3190042</pub-id>
</mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Didona</surname><given-names>D</given-names></name><name><surname>Di Zenzo</surname><given-names>G</given-names></name></person-group>. <article-title>Humoral epitope spreading in autoimmune bullous diseases</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>779</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.00779</pub-id>
<pub-id pub-id-type="pmid">29719538</pub-id>
</mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sreenan</surname><given-names>S</given-names></name><name><surname>Pick</surname><given-names>AJ</given-names></name><name><surname>Levisetti</surname><given-names>M</given-names></name><name><surname>Baldwin</surname><given-names>AC</given-names></name><name><surname>Pugh</surname><given-names>W</given-names></name><name><surname>Polonsky</surname><given-names>KS</given-names></name></person-group>. <article-title>Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse</article-title>. <source>Diabetes.</source> (<year>1999</year>) <volume>48</volume>:<page-range>989&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2337/diabetes.48.5.989</pub-id>
</mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krogvold</surname><given-names>L</given-names></name><name><surname>Skog</surname><given-names>O</given-names></name><name><surname>Sundstr&#x000f6;m</surname><given-names>G</given-names></name><name><surname>Edwin</surname><given-names>B</given-names></name><name><surname>Buanes</surname><given-names>T</given-names></name><name><surname>Hanssen</surname><given-names>KF</given-names></name><etal/></person-group>. <article-title>Function of isolated pancreatic islets from patients at onset of type 1 diabetes: insulin secretion can be restored after some days in a nondiabetogenic environment <italic>in vitro</italic>: results from the diViD study</article-title>. <source>Diabetes.</source> (<year>2015</year>) <volume>64</volume>:<page-range>2506&#x02013;12</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2337/db14-1911</pub-id>
</mixed-citation></ref></ref-list></back></article>